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ABSTRACT 
 
AIM:  
To evaluate aspects of the PMTCT programmes at selected hospitals and clinics in 
Gauteng. 
 
METHOD: 
A cross sectional survey of post partum women in Gauteng was undertaken during April-
June 2006. Data was collected at four hospitals and eight Midwife Obstetric Units (MOUs) 
in four regions in Gauteng. Mothers, irrespective of HIV status, who delivered in the 
previous 48 hours were interviewed. This was followed by a review of the mother’s and 
infant’s records as well as relevant registers.  
 
RESULTS: 
Interviews with, and record reviews, of 182 mother-infant pairs were conducted/obtained; 
69 (38%) at MOUs and 113 (62%) at hospitals. The majority (172 [95%]) of mothers were 
“booked” of whom 155 (85%) had undergone an antenatal HIV test. Forty-two mothers 
(23%) were HIV positive. Nevirapine was issued antenatally to 37/42 (89%) of eligible 
mothers; 30/42 (71%) took it during labour. Three women (8%) received the drug for the 
first time during labour; thus 33/42 (79%) of eligible mothers received nevirapine. Thirty-
two (76%) of babies born to HIV positive mothers received nevirapine. However, in only 
24/42 of mother-infant pairs (57%) was receipt of nevirapine by both parties, recorded.  
There was no significant difference in nevirapine administration rates to mothers at clinics 
compared to hospitals (76% vs. 81%, p=0.71).  Infants were more likely to receive 
nevirapine at clinics compared to hospitals (90% vs. 62%, p= 0.03). 
 
CONCLUSION: 
Four years after introduction of a PMTCT programme in Gauteng, nevirapine uptake and 
administration rates remained sub-optimal, with at least a quarter of eligible (identified) 
women and infants not receiving the intervention. The findings highlight the need to 
prioritise and consolidate PMTCT activities in the province. 
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CHAPTER ONE 
 
LITERATURE REVIEW  
 
Prevention of Mother to Child Transmission (PMTCT) of HIV in the South African 
context   
 
1.1 Background to PMTCT 
The Prevention of Mother to Child Transmission (PMTCT) of human immunodeficiency 
virus (HIV) is a strategy endorsed by the World Health Organization (WHO) in 2000. It is a 
three pronged strategy which includes prevention of HIV among parents to be, prevention 
of unwanted pregnancies among HIV positive women and prevention of transmission of 
HIV from infected mothers to their infants.1 The last prong of the strategy can be achieved 
through the provision of antiretrovirals to HIV infected pregnant women and their infants, 
safe delivery practices, and counselling and support for safer infant feeding practices.1  
 
Mother to child transmission (MTCT) is the predominant method whereby children contract 
HIV.1 In non breastfeeding populations, in the absence of any intervention, 15 to 30 percent 
of children born to HIV infected mothers will contract the virus,1 with the least amount of 
transmission occurring intrauterine (5 to 10 percent) and most infections occurring during 
delivery (10 to 20 percent). Breastfeeding post delivery increases the risk of transmission by 
another 10 to 15 percent.1  
 
Factors responsible for an increased risk of mother to child transmission include:2 
1. Mother’s viral load - with a high viral load and advanced clinical stage increasing 
the risk 
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2. Prolonged rupture of membranes 
3. Infections, including chorioamnionitis 
4. Prolonged exposure to maternal fluids 
5. Instrumental delivery 
6. Breastfeeding - where factors including high viral load, mastitis, cracked nipples 
and altered gut permeability of infant increases the risk of transmission.3 
 
While all these factors play a role, a mother’s viral load and low CD4 count are the two 
major factors involved; thus the need for antiretrovirals during pregnancy to decrease 
transmission rates.4 
 
In 2007, 28.0% of South African women attending antenatal clinics were HIV positive.5   
Worldwide in 2006 it was estimated that 530 000 infants were newly infected with HIV 
and 380 000 children died from AIDS.3    
 
With MTCT of HIV contributing significantly to the under-five mortality rate, 
comprehensive PMTCT packages have been developed and implemented to impact on this 
burden.  
 
 1.2 A Brief History of the Drug Regimens used in Prevention of Transmission of HIV 
from Mother to Infant  
In 1994, the Paediatrics Aids Clinical Trial Group (PACTG) protocol 0760 showed a 
remarkable reduction in transmission of HIV (68%) in infants (tested at 18 months of age) 
when zidovudine (AZT) was provided from the fourteenth week of pregnancy, during 
labour and for six weeks thereafter to the newborn baby. Infants were not breastfeed.6 
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Since this regimen was quite intensive and costly, it would have been difficult to 
implement in resource poor settings.  
 
Following on this, in 1996 the Thai-short course study using AZT from 36 weeks and 
during labour in non breastfeeding populations showed a 50% reduction in of the 
transmission of  HIV.7 
 
In 1999 the Centers for Disease Control and Prevention’s (CDC) West African study, 
using the same drug regimen as the Thai short course study showed a 37% reduction in 
transmission rate in breastfeeding populations.8 The PETRA study results followed in 
2002. In Arm A of the PETRA study AZT and Lamivudine (3TC) were used from 36 
weeks, during labour and for one week after delivery in both mother and infant the 
transmission rate was reduced by 63%. 9 
 
As impressive as these figures were, it was still costly to implement these regimens in 
resource poor settings. 
 
In Arm B of the PETRA study a single dose of AZT and 3TC was administered to the 
mother in labour followed by a week of both drugs to mother and infant. Mothers breastfed 
their babies thereafter. This regimen offered a reduction in transmission of HIV of 42% 
(after 6 weeks).9 
 
In 1999, the HIVNET 012 study in Uganda compared the use of a single 200 mg dose of 
nevirapine (NVP) to the mother in labour followed by a single dose of 2mg/kg to the 
infant, with an intrapartum dose of AZT to the mother followed by AZT to the infant for a 
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week.  The study found a transmission rate of 13% in the NVP group versus 25% in the 
AZT group by 14 to 16 weeks of age in a predominantly breastfed population.10  
 
Based on the HIVNET 012 study, the SAINT study was conducted during 1999 to 2000 
across different centres in South Africa to compare the AZT/3TC regimen (as used in the 
PETRA B study) with a single dose of nevirapine (200mg) delivered to the mother in 
labour followed by 200mg 48 hour post partum and a single dose to the infant (6mg) 24-72 
hours after delivery. The study showed a HIV transmission rate of 12.3% for NVP and 
9.3% for AZT/3TC by eight weeks of age.11 
  
Based on above studies, the WHO recommended in 2001 that in resource poor countries 
the nevirapine regimen would be the simplest regimen to deliver, but also recommended 
that where possible, more complex antiretroviral regimens be offered.1 
 
Other data that followed included a pooled analysis by Leroy, et al. in 2005, which looked 
at HIV transmission rates at 6 to 8 weeks with four different antiretroviral regimens. In 
comparison with placebo, the adjusted odds ratio for HIV transmission was 0.23 for AZT 
and 3TC administered antepartum, intrapartum and seven days postpartum; 0.49 for the 
combination of AZT and 3TC during the intrapartum and postpartum periods only; 0.55 
for AZT only, administered antepartum, intrapartum and postpartum; and 0.60 for single-
dose NVP. Thus, at six to eight weeks, monotherapy with AZT and NVP had similar 
reductions in MTCT, and AZT and 3TC combinations had a greater efficacy in MTCT 
reduction.12 
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In the ANRS 1201/1202 Ditrame Plus cohort in Abidjan, Côte d’Ivoire, in 2001-2003, 
transmission rates at six to eight weeks postpartum were 6.5% (95% CI 3.9–9.1) with ZDV 
plus single-dose NVP, and 4.7% (95% CI 2.4–7.0) when mothers were given both ZDV 
and 3TC from week 32 of gestation, continued for one week postpartum (for both mother 
and child), in addition to single-dose NVP to mother and infant.13 
 
Gray, et al. showed in 2005 that single-dose NVP as post exposure prophylaxis given to 
newborns exposed to HIV tended to reduce MTCT with transmission rates similar to those 
seen in the HIVNET 012 trial. At 12 weeks the cumulative HIV transmission rate was 
14.3% in the NVP arm and 18.1% in babies who received AZT for six weeks post 
delivery. Transmission rates were higher in both groups where breastfeeding was the 
choice of feed.14 
 
More recently in 2006, WHO published its latest recommendations on antiretrovirals in 
pregnancy and preventing infection in infants.15  The guideline recommends that: (1) 
pregnant women eligible for Highly Active Antiretroviral Therapy (HAART) must have 
access to it, and (2) national programmes must adopt more efficacious antiretrovirals 
(ARV’s) for mothers who do not qualify for HAART yet. This regimen consists of 
providing antepartum AZT from 28 weeks of pregnancy or as soon as possible thereafter, 
intrapartum AZT and 3TC plus a single dose of NVP and postpartum AZT and 3TC for 
seven days to mother and single dose NVP and AZT for one week to infants.   
 
Further the guideline states that: “The length of the prophylactic regimen and optimum 
choice of drugs can vary depending on when a woman is identified as infected with HIV.”  
HIV testing may have taken place before pregnancy or may occur at different times during 
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pregnancy, at the time of labour and delivery, or postpartum. Those women, who present 
later in pregnancy or at delivery, should receive the appropriate antiretroviral prophylaxis 
based on the time of her first visit. If the mother presents late in pregnancy and is eligible 
for HAART, then she should be commenced on HAART. If this is not possible, the mother 
should be commenced on ARV’s for PMTCT. Those mothers who present in labour 
should receive a single dose of NVP with AZT and 3TC intrapartum, followed by AZT 
and 3TC for seven days. Infants born to mothers who received less than four weeks of 
antiretrovirals have to receive AZT for four weeks post delivery. Where countries don’t 
have the capacity to implement the new recommendations, the guideline states that “as an 
absolute minimum”, the single dose nevirapine (mother and infant) may be implemented 
with the aim of improving their programmes to provide more effective PMTCT 
regimens.15 
 
1.3 Nevirapine Pharmacology  
Nevirapine, an antiretroviral of the class non-nucleoside reverse transcriptase inhibitors 
(NNRTI), inhibits replication of HIV by blocking the viral reverse transcriptase enzyme. 
Nevirapine is rapidly absorbed when taken orally and has a long half life of approximately 
45 hours after a single dose.16,59 With multiple doses the half life is reduced to 25-35 hours 
as a result of self induction, i.e. the drug is an enzyme inducer and induces cytochrome 
P450. The most common side effects noted with prolonged use include a rash and 
abnormal liver function tests.16 The risk of rash and hepatotoxicity in women on ARV 
treatment has been noted to be higher in women with CD4 counts greater than 250 x 106 
cells per litre.15 Toxicity in infants after a single dose has not been reported. 11,15 
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1.4 Concerns about Nevirapine 
As with other short course regimens resistance to nevirapine may develop rapidly. 
Resistance develops because in the presence of partly suppressive regimens the virus 
selects out for replication of the resistant strain. Once the drug is removed the virus returns 
to replication of wild type virus.15 With nevirapine, as with 3TC, single mutations result in 
a high level of resistance.15 The risk of developing resistance seems to be related to the  
CD4 count and viral load at the time of taking the dose, the viral subtype (more common 
with subtype C than with A and D), the number of doses taken during labour and, the time 
of sampling, i.e. from the time the drug was taken in labour.15,17  The risk of resistance 
doubles when two doses are taken in pregnancy as opposed to one.15 Previous studies, 
including the HIVNET 012 trial, showed resistance developing at 6-8 weeks in 25% of the 
women who received single dose NVP.10 The SAINT study found that 67% of women 
who received two doses of NVP developed resistance.11  
 
However, development of resistance has not been shown to increase MTCT in the present 
pregnancy; neither does exposure to nevirapine decrease the efficacy of PMTCT in 
subsequent pregnancies.15 Resistance to nevirapine can be reduced by administering dual 
NRTIs intrapartum and for a short period following the administration of nevirapine.15,17 
WHO recommends that to prevent resistance to nevirapine, pregnant women eligible for 
HAART should be commenced on HAART and that mothers who receive a dose of 
nevirapine in false labour should not receive another dose when in established labour. The 
infant should be given the dose of nevirapine soon after birth followed by AZT for four 
weeks.15  
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1.5 PMTCT of HIV in South Africa 
In 1994, the results of the first study on the use of AZT as monotherapy to prevent MTCT 
of HIV were published.  This was a tremendous breakthrough for the reduction of HIV 
infection rates in children.  Soon thereafter, the 1994 National AIDS Plan of South Africa 
stated that steps would be implemented to reduce MTCT of HIV. This included voluntary 
counselling and testing (VCT) and conducting research on the use of AZT and other non 
nucleoside reverse transcriptase inhibitors. Progress was slow and in the face of this new 
information being available, yet being unable to help many mothers, many organisations 
including the AIDS Law Project (ALP), the Aids consortium, the Perinatal HIV Research 
Unit (PHRU) and the Treatment Action Campaign (TAC) began lobbying of the 
Department of Health (DoH) to develop a programme to prevent MTCT of HIV. In 1998 
the DoH announced the implementation of five PMTCT pilot sites.18 
 
One of the barriers to developing a nationwide programme was the cost of AZT, and while 
the TAC was working to get manufacturers to reduce the cost of the drug, new opposition 
emerged where the Aids “denialists” sent out the message that antiretrovirals instead of 
improving the immune system had serious life threatening side effects. The government 
and the Minister of Health now questioned the safety of these drugs, and under instruction 
from the President, the health minister ordered the Medicines Control Council (MCC) to 
conduct further research on the drug. This put a halt on developing a national 
programme.18          
 
In 2000, the MCC issued its report that stated that the benefits of AZT outweighed the 
risks, as suggested by the WHO, but it was rejected by the DoH requesting that more 
research be done on the matter. In the interim, in 1999 the results of HIVNET 012 study 
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became available and with the opposition to AZT at the time, the Department of Health 
latched onto this alternative. Nevirapine was now offered as the medicine of choice 
pending the results of the SAINT study. The SAINT study subsequently supported the use 
of nevirapine for the PMTCT of HIV, but there was minimal action by the government.  In 
fact it declined an offer from Boehringer Ingelheim to provide the health department with 
a free supply of nevirapine. The TAC now considered bringing an urgent high court 
application for access to nevirapine.  However, the medicine was not yet registered by the 
MCC for this purpose.18 
 
In August 2000, after the International AIDS conference, the Department of Health 
convened a meeting to discuss new information from the conference. Thereafter, the 
MinMEC committee (a committee consisting of the Health minister and nine provincial 
MEC’s for Health) decided that they would no longer use the policy with AZT, and since 
nevirapine was now registered by the MCC it would be tested at two pilot sites in each 
province over two years. The government failed to reveal information that nevirapine had 
been registered for PMTCT use for another six months.18 
 
With pressure from many clinicians, the TAC and many affidavits later, the DoH planned 
to start setting up the pilot sites by March 2001. This again faced many delays and the 
tension between activists and DoH was rising. In June 2001 the Minister of Health met 
with the TAC, COSATU and a group of paediatricians who formed an organisation called 
“Save our Babies” to advocate for the national availability of nevirapine prophylaxis. Still 
their questions and pleas went unanswered.18 
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By July 2001 the DoH once again faced litigation by the TAC. The initial letter sent to the 
minister and the provincial MEC’s demanded reasons for not making NVP available to the 
public sector and placement of a programme where medical practitioners in the public 
sector were able to prescribe NVP for their patients at their discretion where medically 
indicated. 
After much deliberation many provinces had already set up more than the two pilot sites 
per province. 18 
 
In August 2001, the TAC, Save our Babies and the Children’s Rights Centre filed a 
constitutional claim against the government, stating that the present policy was 
unconstitutional and that the government should be ordered to make nevirapine available 
to pregnant women who delivered in the public sector and to their babies, under the 
judgement of a medical practitioner, and that a national programme be developed 
including VCT, nevirapine to mother and infant and provision of formula feeds.18  
 
On 14 December 2001, a High Court judge ruled in favour of the TAC and others and 
ordered that nevirapine be prescribed where medically indicated and, further, the judge 
“ordered the government to develop ‘an effective comprehensive national programme to 
prevent or reduce MTCT’ and return to the Court with this programme for further scrutiny 
before 31 March 2002.”18  
 
The Minister then appealed to the Constitutional Court against the execution order. In her 
statement to the press she promised to review the present policy with input from “national 
stakeholders” and from the present pilot sites.18  
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By January 2002 the HST completed its initial evaluation of the pilot sites and presented 
their findings at a MinMEC meeting. One of the recommendations of the evaluation stated 
that “while a phased and systematic expansion of comprehensive MTCT services is being 
planned, NVP can and should be provided immediately to all pregnant women who are 
already known to be HIV positive, with appropriate counselling and information.”  This 
information was not made public for a few weeks after the presentation. The Minister 
however stated that she could not take a decision on expansion of the programme until 
May 2002, when the pilot programme would have been in place for one year. In the 
interim, two other processes were taking place, both the Gauteng and Kwazulu Natal 
premiers continued to expand on their PMTCT programmes, and the TAC were planning 
to obtain an execution order from the Pretoria High Court, on part of the judgement that 
ordered that nevirapine be made available where the capacity existed. Back in court in 
March 2002, the High Court judge ruled in favour of the execution order and dismissed the 
government’s application to appeal to the Constitutional Court. Following this the 
government launched an application to appeal the judgement directly to the Constitutional 
Court. The TAC then filed a counter application, stating that the aim of the government’s 
further legal action was to “stultify the execution order.” The hearing took place on 3 April 
2002, and the following day the court refused the government leave to appeal the 
execution order.18 
 
The TAC case continued in court from May through to July 2002. On 5 July 2002, 
judgement was handed down which stated, amongst others, that the government’s policy 
did not fulfil the people’s constitutional right to health care services, that they did not have 
sufficient evidence to claim that nevirapine was unsafe and that the policy was 
discriminatory against poor people who could not pay for the service. Further the 
12 
 
Constitutional Court ordered government “without delay” to remove the restrictions that 
prevented nevirapine from being made available for the purpose of reducing the risk of 
mother-to-child transmission of HIV at public hospitals and clinics that are not research 
and training sites, to make nevirapine available for PMTCT of HIV purposes at hospitals 
and clinics when in the judgment of the attending medical practitioner acting in 
consultation with the medical superintendent of the facility concerned that it is medically 
indicated, and if so to ensure that the mother is adequately counselled and tested, to make 
provisions for counsellors at public hospitals and clinics, to extend the  counselling and 
testing facilities at public  hospitals and clinics and expedite the use of nevirapine for the 
purpose of reducing the risk of mother-to-child transmission of HIV.18  
 
1.6 Description of the PMTCT Programme in South Africa  
Implementation of the PMTCT programme began in 2001 and an increasing number of 
facilities are providing the service every year. By 2006, ninety percent of public health 
facilities provided PMTCT services.19 
 
The first policy on the PMTCT of HIV was developed in 2001, and most of the 
implementation strategies still prevail to date. The programme involved pregnant women 
attending an antenatal clinic where they were offered VCT. Pre-test counselling included 
information about HIV and how to prevent it, information about mother to child 
transmission of HIV and measures to reduce this, information about the testing process, 
discussion about confidentiality, discussion about couple counselling, implications of the 
test result and the meaning of the window period, exposure to stigma and support systems. 
Counselling can take place in a group session and on an individual basis. Women are given 
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the option of “opting-in” i.e. choosing to be counselled and tested. If she so chooses, 
consent is obtained from the mother and her choice recorded in the counsellor’s register.20 
 
A HIV rapid test is performed and mother can choose to receive her result on the same day 
or at a subsequent visit. The result of the test is then recorded in a blood register, the 
counsellor’s register as well as in the antenatal card by means of a share code secret table. 
Once she receives her result the mother is counselled – so-called post-test counselling. If 
found to be HIV positive, post-test counselling would include discussion regarding CD4 
counts, antiretroviral prophylaxis (nevirapine at the time of the study), feeding choices, 
exposure to stigma, support services and safe sex practices.21 Previously only some 
facilities provided CD4 count testing. If CD4 count is <200 or if the mother is clinically a 
WHO category C patient, then where available, mothers can be considered for Highly 
Active Antiretroviral Therapy (HAART) as part of PMTCT Plus.20 
 
Previously, if a mother was found to be HIV positive and if she chose to be part of the 
PMTCT programme, a nevirapine tablet (200mg) was issued from 28 weeks of pregnancy 
to be taken once the mother was in labour. The nevirapine dispensed was recorded in the 
nevirapine register. Previously the protocol stated that if the mother presented in false 
labour and had taken the tablet another dose could be taken again 24 hours after the first 
dose at a subsequent onset of labour or if she remained in labour. (This was subsequently 
changed and a second dose was no longer provided to the mother because of the increased 
risk of inducing nevirapine resistance.) If the mother presented in labour and had forgotten 
to take her tablet then a dose could be administered to her at the facility where she 
presented.  Nevirapine dispensed in labour was also recorded in the labour ward nevirapine 
register. The infant was to receive a dose of nevirapine (2mg/kg) within 72 hours of birth. 
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Feeding options were discussed with the mother again and her choice of feed was recorded 
and supported.20   
 
In February 2008, a new policy on the implementation of a PMTCT of HIV programme 
was issued by the National Department of Health.21 There have been a few changes to the 
previous programme, mostly however along the lines of the drugs being used for PMTCT 
of HIV, with improvements in the quality of VCT provided, counselling and support on 
feeding choices. The policy includes as a fourth prong of the strategy the provision of 
appropriate treatment, care and support to women living with HIV and their children and 
families. 
 
Mothers attending antenatal clinic now undergo two sets of counselling, one as a group 
session and the second on an individual basis. The mother then chooses to have an HIV 
test (or not), and if she does then both verbal and written consent is obtained. A woman 
may refuse to be tested, and if she does then she should be encouraged at further visits to 
undertake the test. If she chooses to have the test done, then the test is performed with a 
rapid kit, and if found to be HIV positive, the rapid test is repeated to confirm the result. 
All mothers are given their results on the same day and undergo post test counselling as 
before. If there is a discrepancy in the two results, a formal HIV ELISA is sent off and 
mothers are asked to return for the results. The HIV test is repeated later in pregnancy at or 
around 34 weeks. 21 
 
With the new protocol, when a mother is found to be HIV positive, CD4 counts are taken 
on the same day; mothers undergo screening for tuberculosis (TB) and are then classified 
according to the WHO HIV Clinical Staging Guideline. Mothers receive continuous 
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support and counselling throughout pregnancy, as well as micronutrient supplementation 
and prophylaxis and treatment for opportunistic infections. 
 
If a mother is found to have a CD4 count <200 or is clinically WHO Stage 4, then she 
should be prioritised for HAART. Note that this is different to the WHO recommendation 
of CD4 < 350 or WHO Stage 3. Those mothers, who do not yet qualify for HAART, 
receive the PMTCT regimen, which consists of AZT from 28 weeks or later followed by 
single dose nevirapine and AZT on a three hourly basis when in labour. Mothers already 
on HAART before pregnancy continue with HAART through pregnancy, labour and 
postnatally; with a change of efivarenz to nevirapine in the first trimester, or they may 
continue with their existing regimen if present later in pregnancy. Mothers who present in 
labour unbooked, will undergo counselling and testing only if they present in early labour 
and will then receive single dose nevirapine and AZT in labour. Those who present in later 
stages of labour will have their testing deferred till after delivery. 21 
 
Infants born to mothers who are HIV positive, will receive single dose nevirapine within 
72 hours of delivery and AZT for 7 days or for 28 days if the mother received less than 4 
weeks of HAART or AZT during pregnancy or single dose nevirapine only.  The dosages 
of nevirapine has been changed to a standard dose of 0.6ml (6mg) for all babies >2kg, and 
a dose of 0.2ml/kg (2mg/kg) for babies <2kg. AZT is also given at a dose of 1.2ml (12mg) 
twice daily, standard for all babies >2kg.21 
 
WHO recommended in 2006 that exclusive breastfeeding should be recommended for HIV 
infected women for the first six months of life unless replacement feeding meets five 
criteria (AFASS criteria) – acceptable, feasible, affordable, sustainable and safe – before 
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that time. When these conditions are met, avoidance of all breastfeeding by HIV infected 
women is recommended.3 The other conditions to be met before replacement feeding is 
chosen include safe clean water, good sanitation, nutritional counselling and growth 
monitoring. 3 If the mother chooses to formula feed, formula is provided free from the 
health facility for a period of six months in South Africa. 
 
The new South African protocol recommends that mothers undergo extensive individual, 
unbiased counselling on the risks of transmission of HIV through breastfeeding and the 
risks with formula feeding and at the same time health workers establish whether the 
mother fulfils the AFASS criteria.21 
 
HIV negative women and women of unknown HIV status are advised to exclusively 
breastfeed for the first six months and then continue to breastfeed for at least two years. 
For HIV positive women, if the mother fulfils the AFASS criteria, then she should 
exclusively formula feed. Milk is provided free for the first six months. If the mother does 
not fulfil the AFASS criteria then it is recommended that the mother exclusively 
breastfeeds the infant for the first six months. Infants must be tested 6 weeks after 
cessation of breastfeeding. If AFASS criteria are then fulfilled then the mother should 
change to formula feeding if the infant tests HIV negative, but if the AFASS criteria are 
not fulfilled, then the mother should continue to exclusively breastfeed until in a negative 
infant the AFASS criteria are fulfilled. If an infant tests positive for HIV in the interim 
then it is advised that the infant be continuously breastfed up to two years even if the 
mother fulfils the AFASS criteria at some point.21 
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Postnatally, mothers on HAART are followed up until 6 weeks post delivery where they 
are transferred to a Comprehensive Care Management and Treatment for HIV and AIDS 
(CCMT) facility.  On-going support to the mother and child for feeding, child health, 
maternal health and social security must also be provided. Infants must be tested at six 
weeks of age, where the HIV-PCR test is performed to confirm the infant’s status, and at 
the same time cotrimoxazole (Bactrim) chemoprophylaxis must be commenced. Those 
infants who test positive must be referred for initiation of HAART.21 
  
Follow up of the mother encompasses nutritional support, counselling and supportive care, 
and treatment of other diseases. Follow up of infant addresses adequate nutrition, 
monitoring growth, monitoring for signs of symptomatic infection, and prevention of 
opportunistic infections.21 
 
1.7 Effectiveness of the South African PMTCT of HIV Programme 
Effectiveness of any PMTCT of HIV programme is determined by the reduction in the 
number of infants infected with HIV. Stringer et al recommend that effectiveness be 
measured by HIV- free survival in resource poor settings.22 
 
To achieve the optimal outcome in a PMTCT program there needs to be: 
       1. An initial high uptake of VCT coupled with a high rate of HIV testing. 
2.  Easily identification of mothers who are HIV positive by health care workers 
(midwives, neonatal, postnatal staff) to facilitate antiretroviral/nevirapine 
administration. 
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3. Adequate counselling on feeding practices so the decision made is based on the 
informed choice of the mother. Mothers need to be supported in their decision by 
health workers.  
4. A system of adequate postnatal follow up of HIV positive mothers and their infants 
and on-going support for mother and infant. 
       5. A structured programme at each facility, with adequate record keeping, adequate  
       supply of test kits, medication and milk supplements. 
 
Therefore in the “PMTCT cascade” problems can occur at different levels. 
 
1.7.1 Voluntary Counselling and Testing (VCT)  
 
1.7.1.1 Uptake of Testing and Follow Up 
VCT serves as an entry point for PMTCT. A high uptake of VCT should therefore increase 
the number of PMTCT participants. Unpublished data from South African National 
Department of Health’s (DoH) Roll-Out Programme 2006, reported fairly low (48%) 
acceptance rate of an HIV test at first antenatal visit.23 The Health Systems Trust reported 
a much improved figure of 75% in 2006/7.24 Though improved, this was still much lower 
than the 95% VCT uptake rate reported in Malawi.23,25 This difference may be attributed to 
the method of counselling and testing. In Malawi an opt-out method was used rather than 
the opt-in method used in South Africa.25,23 Recent studies done in Botswana where HIV 
testing had been changed from voluntary to routine or opt-out have increased rates of 
testing from 47% to 78%.26 In  Zimbabwe, in 2006, Perez noted that 79% of women who 
were not tested for HIV initially reported that they would have undergone testing if the opt 
out method had been implemented.27   
19 
 
Doherty, et al. in the initial report on the national pilot programme noted that at that time 
Kwa-Zulu Natal was the only province using the opt-out method to test mother for HIV. 
Their rates of testing were almost double that of the national average.28 Jayaraman, et al. in 
Canada in 2003 also showed an increase in the rate of HIV testing by 28% in the month 
after the opt-out method was adopted.29 
 
Other factors to consider for low rates of testing at an antenatal visit include quality of 
counselling received, and the shortage of counsellors at some centres resulting in long 
waiting periods for the mothers. 
 
Karamagi, et al. in Uganda in 2003, found that of the 453 women interviewed, only ten 
percent tested for HIV in pregnancy. The barriers to antenatal HIV testing were 
unavailability of voluntary counselling and testing services (44%), lack of HIV counselling 
(42%) and perceived lack of benefits for HIV infected women and their infants.30 
In Kenya, Moth, et al. in 2003 looked at the utilization of PMTCT services at a provincial 
hospital in Kenya.  They found that 52% of clients received PMTCT information at the 
health facility without prior knowledge about intervention. Eighty percent of clients did 
not present for follow up counselling, and 95% of women did not disclose their status to 
their spouses. They also found that inadequate counselling services led to significant drop 
out of the programme, with a 32% drop out at the HIV result stage, a 54% drop out at 
enrolment and an 81% drop out at delivery. Reasons for drop out included fear of a 
positive test result, chronic illness, stigma, discrimination, unsupportive spouse and 
inability to pay for the service.31 
 
20 
 
Peltzer, et al. in 2007 found that in a resource poor setting in the Eastern Cape major 
barriers to provision of PMTCT included access to health care centre, stigma and support, 
PMTCT knowledge, HIV testing and delivery preference. Reasons for lack of disclosure 
included fear of stigma, discrimination and violence.32 
 
Bajunirwe, et al. in Uganda in 2005 showed that the strongest predictor of willingness to 
test for HIV was the women’s perception that her husband would approve of her testing for 
HIV. They were six times more likely to test than those who thought their husbands would 
not approve (OR= 5.6, 95% CI 2.8-11.2). Other predictors of willingness to test for HIV 
were post-primary education (OR = 3.1, 95% CI 1.2- 7.7) and knowledge about rapid HIV 
tests (OR = 1.8, 95% CI 1.01- 3.4).33 
 
Data from the Health Systems Trust (HST) in 2005/6 indicated that almost 100% of 
pregnant South African women attend an antenatal clinic. The figure may be an 
overestimate as the denominator used might be an underestimate.34 However, the uptake of 
HIV testing was only 45% in 2005/6 and 75% in 2006/7.35,24 
 
Since 2001, trials to assess the effectiveness of PMTCT programmes were conducted at 
some centres across the country. Sherman, et al. at Coronation Hospital in Johannesburg 
reported HIV transmission rates of 8.9% in 2002 and Coetzee, et al. at Khayelitsha in Cape 
Town reported transmission rates of HIV of 8.8% in 2003.36,37 Nevertheless, problems 
regarding the functionality of the programme have been described, which included 
significant loss to follow up of mothers and infants due to poor record keeping.36,37  
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Bwirire, et al. in Malawi in 2004 looked at reasons for loss of mothers to follow up in their 
PMTCT programme, they found that the main reasons for loss of follow up included, 
mothers not being prepared for an HIV test and its implications, fear of stigma, 
discrimination and household conflict, lack of support from husbands, the social and 
cultural taboos that are associated with artificial feeding, long waiting times at the 
antenatal clinic and inability to afford the transport costs related to the long distances to the 
hospital.38  
 
1.7.1.2 Nevirapine Administration 
While the national antenatal attendance rate is approaching 100%, and the uptake of VCT 
being disappointingly lower (75%), nevirapine coverage was only 51.7% in 2005/6 and 
only 61% in 2006/7.35,24 
 
The low figures reported are thought to be the result of difficulty in data collection as 
nevirapine administration can take place either antenatally and in the labour ward, thus 
collection from two places proving difficult as well as these figures cannot exclude double 
counting of mothers in both places. Other reasons given include mothers choosing not to 
disclose their status in labour and even taking the dose without reporting to the labour 
ward staff. While identifying an HIV positive mother is imperative to providing both 
mother and baby with nevirapine, the audit on the pilot programme reported that the 
unique identifiers that were developed to identify mother who were HIV positive were 
removed from antenatal cards by patients for fear of stigma.28 None of the national 
program audits discussed the problems with, nor the incorrect use of the coding system, 
nor the effect that this might have on identifying mothers who are HIV positive. 
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A study conducted by Nkonki et al in 2005 in the Western  Cape  at three sites with 
different socioeconomic profiles showed that of the 58 women interviewed a quarter 
(15/58) reported missing their nevirapine dose. For eleven of these fifteen women women 
the reason for not receiving nevirapine was as a result of health system failures including 
not being tested for HIV (5/15) due to lack of counsellors, test kits and consent forms; 
two(2/15) had not been given their test results; and four(4/15) mothers were given 
incorrect information on how to take the Nevirapine or had not  received the nevirapine.39 
Three common reasons for mothers’ not taking the dose were related to personal situations 
including losing the tablet, forgetting the tablet and not collecting the tablet because of 
denial of HIV status. 
 
Stringer, et al. in Lusaka, Zambia estimated city wide effectiveness of their PMTCT 
programme using anonymous cord blood surveillance for HIV antibodies and detectable 
nevirapine drug levels. They found that there were three areas of programme effectiveness 
that were not addressed by most studies, including that women who were HIV negative 
were more likely to refuse the test, laboratory errors caused a proportion of mothers who 
should have received prophylaxis to receive it and one third of women who were given 
nevirapine tablet for self administration, did not actually swallow the tablet. Thus only 
30% of HIV infected women and HIV exposed infants were receiving minimum 
prophylaxis.22  
  
In a more recent study in Lusaka, Zambia, Albrecht, et al. reviewed factors that determined 
adherence to nevirapine in mothers and babies. They found that mothers who delivered at 
home, had no high school education or delivered low birth weight babies were less likely 
to receive nevirapine. Babies born at tertiary centres, with low Apgar scores or who died in 
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the neonatal period were also less likely to receive nevirapine mainly because of other 
interventions that were prioritised.40 Colvin, et al. in their study at three different 
socioeconomic sites in South Africa reported that the higher socioeconomic status of the 
mother and the better the counselling received, the higher the chance of the mother 
receiving nevirapine (OR1.17, p=0.03; and OR=1.55, p=0.008, respectively).41 
 
According to the District Health Barometer the national nevirapine coverage for babies in 
2005/6 was reported in excess of 70% with some districts reporting 100% coverage.35  This 
compared favourably to the previous 2006 DoH survey, where just over a third (37%) of 
mother-infant pairs received nevirapine.23  These high rates however might also be an 
overestimate as they account for the number of babies given nevirapine born to those 
mothers who are identified as being HIV positive rather than of all HIV positive women. 
In 2006/7 however the rates had dropped to about 47%, the lower rates thought to be as a 
result of better record keeping.24 
 
Poor rates of nevirapine administration to babies are most likely the result of an inability to 
identify all HIV positive mothers. Low rates of nevirapine administration to babies was 
also reported in Malawi, with a rate of 45%, mainly due to the high loss to follow up of 
mothers by delivery (68%).25 
 
Spinsley, et al. of the Elizabeth Glasier Paediatric Aids Foundation evaluated their MTCT 
programme in resource limited settings across different countries. Of the 2.6 million 
women who accessed their services, 92.9% of women were counselled and 82.8% 
accepted testing. Of those who had tested positive, 75% received antiretroviral prophylaxis 
and 45.6% of infants born to HIV positive mothers received prophylaxis.42 
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Onah, et al. at a tertiary hospital in Nigeria, showed high rates of VCT uptake (almost 
100%), as well as high rates of nevirapine administration to mother and infant, where 24% 
(10/41) had taken their nevirapine issued to them during antenatal period and the rest 
(31/41) received their antiretrovirals on arrival at the labour ward. All infants received 
nevirapine at birth. Their high rates of VCT acceptance could be related to mothers 
receiving both group counselling and individual counselling (96%), and changing to the 
opt-out system of testing. Apart from reporting that the 10 mothers who received their 
antiretrovirals antenatally resided outside of town, there is no mention as to why all of the 
other mothers received their dose in the labour ward (perhaps this is part of the policy).43 
 
Geddes, et al. at McCords Hospital in Durban over the period 2004 to 2005, also showed 
high rates of VCT (100% received counselling and 91% underwent testing). There was an 
11% (36/338) loss of HIV positive mothers to follow up, 97% of women received 
prophylaxis, Ninety eight percent of the live babies born to HIV positive mothers who 
delivered at the hospital received nevirapine and 75% received AZT as well. 44 They 
demonstrated very high rates along all steps in the “cascade”, in this state-aided hospital, 
however they also mention that there could possibly be a selection bias in their patients - 
they were socio-economically better off than those attending public facilities. 
 
High rates of nevirapine administration to babies have also been described in the Health 
Systems Trust review of the National Pilot Programme in 2002 reported that though 55% 
of HIV positive mothers received nevirapine, 99% of babies born to HIV positive mothers 
received nevirapine.28 Once again this is a percentage of the mothers identified as HIV 
positive. Sherman et al also reported figures of 95% at Coronation Women and Children’s 
Hospital in 2004.36 
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1.7.1.3 Feeding 
Since the initial recommendation that exclusive breastfeeding for four to six months 
reduces the transmission of HIV from mother to infant, there have been some controversy 
regarding the potential risk of transmission versus the benefit of breastfeeding and 
therefore what the optimal feed for the infant would be. There has also been concern that 
there has been a reduction in the number of mothers breastfeeding both in the HIV positive 
and HIV negative mothers and that support for breastfeeding has been reduced. 
 
Most studies report high rates of feeding counselling received by mothers antenatally and 
postnatally. The 2002 audit of pilot sites reported that mothers who received counselling 
were given the option of choosing to formula feed exclusively for six months or breastfeed 
exclusively for 4-6 months with early weaning. At discharge 58% of mothers chose to 
formula feed and 42% chose to breastfeed. There were a higher percentage of mothers who 
intended to formula feed in the rural areas compared to the urban areas.28   
 
Geddes, et al. were also concerned that more than 90% of mothers chose to formula feed in 
their sample.44 Onah, et al. in their study in Nigeria showed that 98% of HIV positive 
mothers received counselling on feeding, with 100% choosing to exclusively formula 
feed.43 Coetzee et al. in Khayelitsha, on interviewing mothers after 6 weeks found that 
only 4 mothers (<1%) were mixed feeding and the rest reported exclusive formula 
feeding.37 
 
Buskens, et al. in 2007 looked at the infant feeding practices of mothers in low resource 
settings in three African countries. They found that despite PMTCT programmes, most 
infants underwent very early mixed feeding. Reasons for mixed feeding included the belief 
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that it was necessary to give infants water, disempowered mothers felt that their breast 
milk was insufficient and relatives and breadwinners played an authoritarian role on the 
modes of feeding, especially in situations where the mother did not disclose her status. 45 
Sadoh, et al. in Nigeria evaluated the feeding practices of HIV positive mothers in the first 
six months of their babies’ lives. They had two cohorts of patients, a PMTCT cohort and a 
non-PMTCT cohort. None of the babies in the PMTCT cohort were breastfed and all in the 
non PMTCT cohort were breastfed. Mixed feeding was high in the non-PMTCT cohort 
(70.45%). Formula was inadequately prepared in 77.4% of the non-PMTCT cohort and in 
18.6% of the PMTCT cohort.46 
 
Chopra, et al. in 2008, assessed the feeding components of PMTCT programmes in four 
African countries. They found that infant feeding options were mentioned in only 48% of 
observed counselling sessions and in only 5.5% was it discussed in depth. Overall there 
was poor knowledge of the risk of transmission from mother to child through breastfeeding 
by health care workers. Perceptions by the community on the dangers of HIV transmission 
through breastfeeding as well as the stigma associated with not breastfeeding made it 
difficult for mothers to sustain any optimal feeding plan.47 
 
1.7.1.4 Post-natal Follow-up 
Further care of the mother and the infant after delivery involves identification and 
management of an HIV infected infant as well as managing the mother’s infection. This 
requires integration of health care services responsible for PMTCT and paediatric and 
adult care.   
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Most studies done on the operational effectiveness of PMTCT programmes have 
experienced loss of follow up of infants post delivery. Sherman, et al. at Coronation 
Hospital experienced a 70% loss to follow up by 4 months of age.36 Doherty, et al. 
reported a 50% loss to follow up of infants.28  
 
Ginsburg, et al. in 2007 assessed PMTCT programmes across 18 countries supported by 
the Elizabeth Glasier Pediatric AIDS Foundation. During their 18 month study period 10% 
of mothers tested were found to be HIV positive. Across 14 countries 86% of clinics 
reported having fewer than 10 patients on HAART at the time with improvement where 11 
clinics reported having 25 or more patients on HAART.  At most of these clinics the site 
where mothers obtained their HAART was separate to the PMTCT site. Approximately 
nine percent of infants were followed up and received cotrimoxazole prophylaxis.48  
 
1.8 A Gauteng PMTCT Perspective  
Gauteng has 27 hospitals offering paediatric care and over 320 provincial and local 
authority clinics providing antenatal and/or obstetric services, including PMTCT. 
Approximately 150 000 babies are born in Gauteng each year with two-thirds of births 
occurring in hospital and one-third at the clinics. Each of the midwife obstetric units (MOU) 
provides a PMTCT programme based on the national PMTCT guidelines. 
The Health Systems Trust review of the National Pilot Programme in 2002 reported a 79% 
uptake of VCT in Gauteng, 58% administration of nevirapine to mothers and a 98% 
administration of nevirapine to infant. Poor rates of nevirapine administration to mothers 
was attributed to poor understanding of the regimen by mothers and non-disclosure of their 
HIV result by mothers to staff in the labour ward.49 
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According to the District Health Barometer the 2006/7 antenatal HIV prevalence in the 
metro regions in Gauteng ranged from 27% to 32%, the nevirapine coverage to the mother 
ranged from about 67% to about 90% (in the City of Johannesburg) and the nevirapine 
coverage for babies ranged from 24% to 42%.24 
 
1.9 Conclusion  
For an effective PMTCT programme there needs to be a high rate of acceptance of HIV 
testing, knowledge of women’s status and understanding the need for PMTCT of HIV. 
Easy identification of mothers who are HIV positive leads to more mothers and babies 
receiving nevirapine. Adequate counselling and support assists mothers in making their 
feeding choice, and may improve follow up of infant and mother. Imperative is the early 
identification of HIV infected infants which is dependant on documentation of the mothers 
result, as well as ongoing management of the mother’s and infants infection, preventing 
opportunistic infections and providing nutritional support. For optimal care of mother and 
infant there needs to be better intergration of mother and child services.  
 
To reduce the spread of HIV and the number of deaths from HIV in the paediatric 
population,  PMTCT services need to be strengthened. Improvement in antiretroviral 
regimens is but one step. We need to overcome the stigma associated with HIV, provide 
support and encourage mothers to know their status and understand the need for PMTCT. 
Changing our opt-in policy to an opt-out policy and improving our counselling services 
and involving partners and spouses will improve our VCT uptake rates. Optimal feeding 
plan for each mother must be decided individually through unbiased counselling, giving 
mothers all the facts they need and then providing support for their choice.  
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PMTCT programmes are an entry point to family care and comprehensive HIV/AIDS 
treatment and care. Opportunities to prevent infection cannot be missed. 
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CHAPTER TWO  
 
INTRODUCTION 
 
In Gauteng, antenatal and obstetric services are offered at both hospitals and clinics 
including Midwife Obstetric Units (MOUs). The Midwife Obstetric Units (MOUs) belong 
to the provincial authority. MOUs and hospitals provide obstetric care 24 hours a day 
whereas most ordinary clinics provide antenatal services during working hours, five days a 
week.  A survey by the Health Systems Trust in 2003, looking at primary health care 
services in Gauteng, indicated that 22% of facilities providing antenatal care, had services 
available for five days a week.50The number of deliveries at MOUs includes anything 
between three and ten babies a day.     
 
At the time of the study most facilities ran their PMTCT programmes according to the 
2001 National PMTCT Protocol. This included: 
• counselling, followed by voluntary testing and post test counselling,  
• recording of the result on mother’s antenatal card according to the coding system,  
• issuing nevirapine to HIV positive mothers,  
• recognising babies exposed to HIV and issuing nevirapine prophylaxis to them,  
• counselling and supporting mothers’ feeding choice,  
• issuing of milk if the mother chose to formula feed, and  
• follow up of mother and infant with infant testing by means of the HIV DNA-PCR 
test at six weeks of age. 
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In addition to this, some units were able to offer HIV positive mothers CD4 testing which 
enabled mothers eligible for HAART to be referred to an HIV clinic. While some facilities 
had their PMTCT programmes well in place and running for a long time, one facility had 
started their MOU service a month before this study.  
 
When the functionality of the pilot sites was assessed by Doherty et al, many problems 
were found at each facility. These problems included inadequate space for the addition of 
dedicated rooms for counselling and testing, inadequate staff including lay counsellors to 
counsel and test patients as well as poor ongoing post test counselling and support.  Supply 
of test kits often ran out. Regarding nevirapine administration to mother and baby, noted 
problems included inadequate information given to the mothers on when to take 
nevirapine, difficulty identifying HIV positive mothers and therefore their babies and 
recording of the administered dose. Difficulty recognising mothers was a result of failure 
to disclose their status and coding systems not being implemented properly. Further, rates 
of testing of infants at follow up were very poor, owing to discrepancy as to when to test 
the infant, poor referral systems, ineffective use of tracking or coding system and 
reluctance of mothers to disclose their status. Initially, infants were tested via the ELISA 
method at 12 months of age, which has subsequently changed to the DNA-PCR method.49 
 
The Millennium Development Goals stress the importance of reducing the under- five 
mortality rates by reducing the number of cases of and the spread of HIV. Worldwide, new 
studies are taking place regularly to determine the most effective regimen of ARV’s to 
prevent MTCT.   
 With the move towards providing mothers with dual or triple therapy, the aim of my study 
was to assess whether the PMTCT programme in place at the time of the study was 
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running effectively and whether the health system could support a more complex drug 
regimen. 
 
2.1 AIM: 
The aim of the study was to evaluate aspects of the PMTCT programmes at selected 
hospitals and clinics in Gauteng 
 
2.2 OBJECTIVES: 
Primary objective: 
To determine the proportion of eligible mother-infant pairs receiving nevirapine. 
Secondary objectives: 
1. To establish VCT uptake and HIV positivity rates in women delivering at the selected 
sites. 
2. To determine the feeding practices of mothers during the first 48 hours of their baby’s 
life. 
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CHAPTER THREE  
 
METHODS 
 
3.1 Study Design 
 
A cross sectional survey involving post partum women was undertaken across four Gauteng 
hospitals and eight midwife obstetric units (MOUs) between April and June 2006. The 
study was primarily descriptive, but had analytic components. 
 
3.2 Study Population 
 
The study population consisted of all mothers who delivered babies in Gauteng.  
Approximately 150 000 deliveries occur in Gauteng each year.  At the time of the study 
Gauteng had 27 hospitals and 320 local and provincial clinics that offered antenatal care 
and/or obstetric services. 
 
3.3 Study Sample 
 
The study sample was obtained from mothers who had delivered babies in the preceding 48 
hours from twelve PMTCT sites in Gauteng province. The sites were chosen on a 
convenience basis.  
 
A sample of between 150 to 200 mother infant pairs from both the hospital and midwife 
obstetric unit (MOU) sites, with approximately 45 HIV positive mothers was anticipated in 
the study period. The study period was based on the period available for the researcher to 
visit the sites and complete data collection. 
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Exclusion criteria were: (a) mothers who had delivered stillbirths and (b) mothers who were 
too ill to be interviewed (e.g. being ventilated or heavily sedated). 
 
The size of the sample was based on an estimate of the number of deliveries at each site 
over the time period allocated for data collection (2 months). It was estimated that the 
study sample would include 0.25% of the (annual) study population, i.e. mothers 
delivering in Gauteng in one year. 
 
3.4 Study Sites 
 
Four hospitals and eight MOUs were selected, with one hospital and two MOUs each from 
four of the five regions in Gauteng.  Site selection was based predominantly on 
convenience but also influenced by availability and approval to conduct research at each 
facility. Only four regions in Gauteng were selected due to time and logistical constraints 
(the fifth region was the smallest and the furthest north). One hospital, and two MOUs, 
was selected in each region in an attempt to improve generalisability. This distribution 
would also allow enrolment of approximately equal number of study participants overall at 
hospitals and MOUs. 
 
The sites selected included: 
 
Johannesburg Central : Chris Hani Baragwanath Hospital 
                                      Chiawelo Clinic 
                                      Zola Clinic 
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Lillian Ngoyi Clinic was selected initially instead of Zola Clinic. However when permission 
was requested from Gauteng Health Regional Office to conduct research at MOUs, 
permission was denied for Lillian Ngoyi Clinic but granted for Zola Clinic (which was 
recommended by the Gauteng Office). The reason for refusal of permission was not stated 
in their response. 
 I anticipated that this change in the study site would influence the sample size calculation 
as Lillian Ngoyi Clinic has on average more deliveries per month than Zola Clinic. 
 
West Rand: Leratong Hospital 
                    Mohlakeng MOU 
                    Bekkersdaal MOU 
The West Rand has only three facilities providing midwife/obstetric services.  The two 
selected for study were chosen on a convenience basis. 
 
East Rand: Tembisa Hospital 
                   Phola Park MOU 
                   Esangweni MOU 
The East Rand has four facilities providing midwife/obstetric services and the two chosen 
were convenient in terms of travelling distance. 
 
Tshwane:  Pretoria West Hospital 
                  Laudium CHC 
                  Shoshanguve CHC 
Laudium CHC had opened its MOU section one month prior to our study. I anticipated that 
implications of this on the study could be both positive and negative. Staff would be very 
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familiar with the PMTCT programme as they would have recently received in-service 
training (positive), but ‘teething problems’ were to be expected (negative). 
 
Three of the four hospitals selected were secondary (regional) hospitals.  Chris Hani 
Baragwanath Hospital served both secondary and tertiary roles in its region. Both Chris 
Hani Baragwanath and Pretoria West hospitals had an independent research unit monitoring 
their PMTCT programmes. Pretoria West Hospital was one of the facilities included in the 
initial national PMTCT pilot study. 
 
3.5. Study Procedures 
 
A study tool consisting of four parts was designed by the researcher (Appendices A-D).  
The first part involved an interview with each mother (conducted by the researcher). The 
second part involved a review of each mother’s and baby’s records. The third part included 
a cross-check of nevirapine administration in the mother/baby’s file with hospital and 
clinic records. The fourth part consisted of an interview with the manager in charge of the 
PMTCT programme at each centre. 
 
Part 1- Interview with mother 
The postnatal wards were visited and all mothers who had delivered babies in the 
preceding 48 hours were approached for consent to participate in the study. Mothers were 
selected on a convenience basis, but an attempt was made to interview all eligible women 
present in the ward/unit on the study day. Mothers received both an information sheet as 
well as a verbal description of the purpose of the study prior to enrolment. 
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A series of questions (Appendix A) were asked to each mother in order to determine:    
1. If the mother had received antenatal VCT and if she was aware of her results 
2. If the mother was provided with nevirapine at an antenatal visit  
3. Details regarding the administration of nevirapine in labour 
4. Whether the mother was aware of her baby receiving nevirapine 
5. Whether the mother had received any feeding counselling before or after delivery 
6.   If the mother was aware of what her baby had been fed and what her intended 
feeding choice was.  
 
Part 2- Record Review 
The second part (Appendix B) included an assessment of:  
A)  The mother’s hospital/clinic file and antenatal card to: 
1. Determine whether the mother received VCT, and whether she opted to have an 
HIV test (data from antenatal card). 
2. Assess the recording of a HIV test (in antenatal card). 
3. Determine whether the mother was given nevirapine antenatally (to ingest when in 
labour). 
4. Determine whether the mother’s receipt of nevirapine in labour was documented in 
her file. 
5. Assess if any record existed of the baby’s initial feeding method and whether any 
record was made of postnatal counselling regarding feeding present. 
 
B)  The mother’s or baby’s file, to determine if a dose of nevirapine administered to the 
baby had been recorded as well as to determine the feed offered to the infant immediately 
after, and following, birth.  
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Part 3- Cross checking 
The third part (Appendix C) included a cross-check of the hospital or clinic’s nevirapine 
registers with the mother’s or baby’s file to validate the administration of nevirapine. 
 
Part 4- Interview with unit manager 
The fourth part (Appendix D) included an interview with the manager or person in charge 
of the PMTCT programme at each site to understand the availability of protocols and how 
they were being followed at each site. 
 
3.6 Study Measurements 
 
1. The rate of VCT uptake was calculated based on the interview with mother as well as 
from the mothers’ records (both accepted as “proof”). 
2. The confirmed HIV positivity rate was calculated based on a record of a positive result or 
disclosure from the mother. 
3. The rate of nevirapine administration to a mother was obtained from mother’s report of 
nevirapine receipt either antenatally or in labour, as well as from a record of administration 
in either the antenatal card, the labour file or the nevirapine register. 
4. The rate of nevirapine administration to baby was obtained from a record of 
administration in the baby’s records and/or from the unit’s nevirapine register. 
5. Initial feed to baby data was obtained from the baby’s records and/or from the mother’s 
history. 
 
All interviews were conducted by a single researcher (FI) to avoid interviewer variability. 
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For open questions, pre-empted answers were coded by the researcher to maintain 
uniformity.  For example, with questions where more than one answer would be possible, 
the possible responses that the researcher anticipated would be offered by participants were 
pre-emptively allocated numbers, e.g. 1-6 and the mother’s response would be captured as a 
number, unless the response was unique and unexpected, in which case it would be captured 
verbatim.  
 
3.7 Pilot Study  
 
A pilot study was conducted at two sites, Alexandra Health Centre (a MOU) and 
Johannesburg General Hospital, to test the study tool and to incorporate any changes before 
the main study, and to provide the researcher with a guide to the time needed to complete 
the four components of the study. A total of thirty mothers were interviewed. With the 
initial questionnaire the flow of questions regarding testing for HIV till taking nevirapine in 
labour was poor. Further questioning on when nevirapine was issued to the mother and 
when nevirapine was taken were necessary to assess where in the process the problem 
arose. The initial questionnaire was not specific in this matter.  The changes made to the 
study tool after the pilot study included adding on questions on disclosure of mother’s HIV 
status, rephrasing the questions on nevirapine receipt  antenatally and in labour to make the 
question clearer to the participant, and including more detailed questions or post delivery 
counselling, feeding practices and follow up of the infant. 
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3.8 Statistical Analysis 
 
Data was initially entered onto an Excel spreadsheet (Microsoft, Seattle, USA), then 
analysed using Statistica statistical software version 6.0 (Statsoft, USA) and Epi Info 
version 3.3.2 (CDC, Atlanta, USA).  Most data was descriptive but comparison of data was 
done using standard statistical tests such as the chi-square test (or Fisher exact test, if <5 
observations per cell) for categorical data. A p-value <0.05 was considered significant. 
 
3.9 Ethical Considerations 
 
Ethical approval was obtained from the University of Witwatersrand’s Committee for 
Research on Human Subjects (Medical) (Clearance No. M060328). (Appendix E). 
Permission was obtained from Gauteng Regional Office, Pretoria Regional Office, 
Ekhuruleni district, West Rand Regional Office and the Chief Executive Officers of all the 
hospitals.  
 
Memos were sent to each facility providing them with the dates of the scheduled visits and 
the unit managers were phoned a few days in advance to obtain their permission and remind 
them of the visit. 
 
Information sheets were provided to all mothers and facility managers (Appendices F-G), 
and written consent was obtained from all those who chose to participate (Appendix H). 
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3.10 Financial Considerations 
 
A Faculty Research Committee Individual Grant was obtained from the University of 
Witwatersrand Health Sciences Research Committee. This covered stationery, printing, 
telephone and transport expenses. 
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CHAPTER FOUR   
 
RESULTS 
 
Two hundred and twelve mothers were approached for consent to participate in the study. 
Thirty (14%) mothers refused to participate. One hundred and eighty two mother-infant 
pairs (86% of those approached) were included in the study. 
 
Of the 182 participants, 113 (62%) delivered at hospitals and 69 (38%) delivered at clinics, 
a hospital: clinic ratio of 1.6, which approximated the general ratio of hospital to clinic 
deliveries in Gauteng at the time. However, the hospital: clinic ratio differed in the various 
regions. Table 1 shows the distribution of participants who delivered infants at the different 
regions. 
 
Table 1:  Distribution of study participants between hospitals and clinics, per district, in 
Gauteng 
 No. of patients Hospital Clinic Hospital:Clinic ratio 
Johannesburg Central    59   40     19 2.1 
East Rand    33   17     16 1.1 
West Rand    49   36     13 2.8 
Tshwane    41   20     21 0.95 
Total   182  113     69 1.6 
 
4.1 Demographics. 
The demographic details of mothers included in the study are displayed in Table 2. 
Their mean age was 26.2 years, most (73%) were unmarried, two-thirds (65%) had 
attended secondary school, few (20%) were employed and the vast majority (93%) lived in 
Gauteng.  
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Table 2: Demographic details of mothers included in study (n=182) 
Detail Result 
Age Mean: 26.2 ±5.9 years 
Range: 17-47 years 
Marital status: N (%) 
                         Unmarried 133 (73) 
                         Married traditionally 16 (9) 
                         Married legally   32 (17) 
                         Separated/Divorced 1 (1) 
Education: N (%) 
                       Secondary school education 120 (66) 
                       Primary school education 13 (7) 
                       Tertiary level of education 33 (18) 
                       No formal education 16 (9) 
Employment: N (%) 
                   Mothers employed 36 (20) 
                   Partners employed 152 (84) 
Place of Residence: N (%) 
                   In Gauteng 169 (93) 
                   Other Province 13 (7) 
 
 
4.2 Booking During Pregnancy 
One hundred and seventy two (95%) of study participants had “booked” during their 
pregnancy. Ninety-two percent of mothers (168/182) attended an antenatal clinic during 
their pregnancy, 26% (48/182) attended a hospital, 30% (55/182) attended a general 
practitioner and 4% (7/182) visited a traditional healer. Many had attended more than one 
point of service delivery during the pregnancy. 
  
4.3 Voluntary Counselling and Testing (VCT) 
An HIV test was offered to almost all (95%) of mothers attending an antenatal clinic; 45% 
of women attending a hospital, 37% attending a general practitioner and none of the 
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mothers attending a traditional healer. The mothers’ partner was present at the time of 
VCT session in 12% of instances. Eighty five percent (155/182) of mothers had their HIV 
test performed antenatally, 2% (3/182) tested postnatally and 13% (24/182) failed to 
receive VCT or chose not to test throughout their pregnancy or post delivery. 
 
4.4 HIV Seroprevalence 
The confirmed HIV positivity rate in this study sample was 23% (42/182). The HIV 
positivity rate was much lower in the West Rand region (12%), compared to the other 
regions which ranged from 22% to 27%. This was statistically significant (6/49[12%] vs. 
36/133[27%], p=0.04). 
 
Of those participants who had tested for HIV, most received their result from a counsellor 
(46%) followed by a nurse (37%), while few received their result from the clinic doctor 
(3%) or a general practitioner (6%).  More than three-quarter (77%) of participants received 
their results immediately after counselling and testing.  About the same number (73%) of 
those who tested antenatally reported that they received post test counselling, leaving more 
than a quarter of the sample who claimed that they did not receive this service. 
  
4.5 Disclosure 
Of all mothers who tested for HIV, 67% (106/158) had disclosed their results to their 
partners and 46% (72/158) disclosed to another person. However of the mothers who 
tested positive for HIV, only 36% (15/42) disclosed their results to their partner and 19% 
(8/42) disclosed to someone else (Figure 1). This difference between HIV status and 
disclosure was statistically significant, with participants who tested positive much less 
likely to disclose their status to their partner (15/42 [36%] vs. 91/116 [78%]; p<0.001). 
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Figure 1: Number of women who disclosed their HIV result to their partner and/or 
someone else  
 
 
 
4.6 Recording of Test Result 
Mothers’ HIV results were recorded in the antenatal card and/or in the admission files. 
This was either in the form of the national PMTCT coding system, or marked as positive 
or negative in admission files, or the specific unit had its own coding system, e.g. “VCT 
positive” or “VCT negative”. In some cases more than one method was present, coded in 
the antenatal card and marked as positive or negative in the admission file. Figure 2 shows 
the distribution of the various methods used. The “other” category included facility 
specific coding methods, e.g. VCT +ve, IC +ve. 
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Figure 2: Methods used to record the mother’s HIV result in her records  
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4.7 Nevirapine  
During the interview with the mothers, they were asked about their knowledge of 
nevirapine. Their response was recorded and immediately coded by the researcher as either 
acceptable or not acceptable. An acceptable explanation was considered to be one where 
anything to do with the prevention of transmission of HIV from mother to infant was 
mentioned. Sixty four percent (116/182) of all mothers interviewed claimed that they knew 
what nevirapine was; however only 53% (97/182) of all mothers had a reasonable 
explanation for its use. All the HIV positive mothers could adequately explain nevirapine’s 
function. There was a significant difference found between HIV positive and HIV negative 
mothers with regard to adequate knowledge on nevirapine and its uses, with HIV positive 
mothers having a better knowledge overall (42/42 [100%] vs. 55/140 [39%], p=0.0002).  
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4.7.1 Nevirapine Administration to the Mother 
Forty two mothers were identified as HIV positive. Of the 42 mothers, 37 (89%) received 
nevirapine antenatally. Reasons for the five mothers not receiving nevirapine antenatally 
included: 
- failure of health care workers to recognise the mother as being HIV positive (n=2),  
- failure of mother to disclose her status to health care workers (n=2),  
- mother was tested early in pregnancy and asked to come back at a later stage (28 
weeks of pregnancy) to collect her nevirapine (n=1).  
 
Almost all of the mothers who received their tablet antenatally were adequately counselled 
about when to take the tablet in the researcher’s opinion. Once again this counselling was 
offered by either a nurse or a counsellor. 
 
Of the 37 HIV positive mothers who received nevirapine antenatally, 30 (81%) took the 
tablet (given to them at antenatal clinic) when they went into labour, and 3 (8%) took their 
tablet in the labour ward (tablet given to them when they presented in labour). Four mothers 
(11%) did not take the medication (figure 3). 
 
 
 
 
 
 
 
 
48 
 
Figure 3: Administration of nevirapine to HIV +ve mothers during pregnancy and labour 
 
 
 
 
 
 
 
 
 
 
  
The seven mothers who did not take the dose given to them at antenatal clinic reported 
losing the tablet or forgetting the tablet at home, or that they were visiting at a place away 
from home and had not had the medication with them when they went into labour.  
 
Some of the reasons for the four mothers who received nevirapine antenatally but presented 
in labour without having taken the tablet, and had not been given another dose of nevirapine 
included: 
-  a mother presented fully dilated and about to deliver it was too late for her to 
receive the dose,  
- inconsistencies with what to do if a mother presented in true labour after having 
presented in false labour more than 48 hours prior and had taken her initial dose, 
- hesitancy to give a mother who disclosed her status on presentation in labour ward a 
dose of nevirapine without proof of a positive status, 
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- some mothers who had booked at another province and presented in labour at a 
facility in  Gauteng without a record of an HIV result, were not retested; reasons for 
failure to retest mother is unknown. 
 
Overall, 33/42 (79%) of mothers who were HIV positive took nevirapine during labour (on 
history or by record review). However, for only 29/33 participants (88%), was receipt of 
nevirapine by the mother recorded in her file or in the nevirapine register. 
 
Nevirapine and place of delivery:  There was no difference demonstrated between 
nevirapine administration to a mother at a clinic as opposed to a hospital during labour, 
(16/21[76%] vs. 17/21[81%], p=0.71). 
 
Nevirapine and employment: No statistical difference was demonstrated between being 
employed or unemployed and taking nevirapine in labour, (8/10 [80%] vs. 25/32 [78%], 
p= 0.90). 
 
Nevirapine and any level of education:  No statistical difference was demonstrated 
between receiving any formal education versus no formal education and taking nevirapine 
in labour, (27/34 [79%] vs. 6/8 [75%], p=0.79). 
 
Nevirapine and living with partner: No statistical difference was demonstrated between 
living with a partner, or not living with a partner, and taking nevirapine in labour, (21/25 
[84%] vs.12/17 [71%], p=0.3). 
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4.7.2 Nevirapine Administration to Infant 
Figure 4 shows the difference in nevirapine administration to mother and infant at clinics 
and hospitals.  The rate of nevirapine administration to infants was based on a record of 
nevirapine administration in the infant’s file or in the nevirapine register.  
 
Figure 4: Nevirapine administration to mothers and infants at the clinics and hospitals 
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There were a total of 63 clinic deliveries. Twenty one (33%) of the mothers at clinics were 
HIV positive (half of all HIV positive mothers in the full study sample). Of those who 
were positive, overall, 16/21 (76%) women received nevirapine in labour. Nineteen (90%) 
of the infants born to HIV positive mothers received nevirapine. There were a total of 113 
hospital deliveries, of whom 21 (19%) were HIV positive. Overall 17/21(81%) of the HIV 
positive mothers received nevirapine in labour and 13 (62%) of the infants born to HIV 
positive mothers received nevirapine.  Infants were more likely to receive nevirapine at a 
clinic than at a hospital, (19/21 [90%] vs.13/21 [62%], p=0.03). 
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Overall: 
• 79% (33/42) of HIV positive mothers received nevirapine, 
• 76% (32/42) of infants born to HIV positive mothers received nevirapine, and in 
• 57% of cases was receipt of nevirapine by both mother and infant recorded. 
 
Only 26/33 mothers (78%) who had received nevirapine were aware or informed after 
delivery that their infant had received nevirapine. Table 3 summarises the above data: 
 
Table 3: Summary of receipt of nevirapine by mother and infant at the clinics and hospitals 
 Total 
N (%) 
Clinic 
N(%) 
Hospital 
N(%) 
p-value 
HIV positive N=42 N=21 N=21  
Mothers who received nevirapine 33 (79) 16 (76) 17 (81) p=0.7 
Infants who received nevirapine 32 (76) 19 (90) 13 (62) p=0.03 
 
 
4.8 Feeding 
 
4.8.1 Counselling 
All mothers were asked if they had received any infant feeding counselling during 
pregnancy and about their future infant feeding choices. Seventy eight percent (142/182) 
reported to have received some form of counselling.  
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Figure 5:  Feeding options recommended to HIV positive and negative mothers by staff 
during antenatal counselling 
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Of all the HIV negative mothers counselled, 90% reported that they were advised to 
breastfeed only or exclusively breastfeed for four to six months, 3% were advised to 
choose between formula and breastfeeding and 2% were advised to formula feed only. 
Five percent could only recall general information about feeding, namely how to position 
infant when feeding, how frequently to feed infant, how to sterilise bottles, etc. (figure 5). 
 
Amongst the HIV positive mothers, 22% (9/42) were advised to breastfeed only or 
exclusively breastfeed for 4-6 months, 62% (26/42) were advised to choose between 
formula and breastfeeding, 12% (5/42) were advised to formula feed only and 5 % (2/42) 
recalled receiving general information only (figure 5). 
   
Significantly more HIV negative mothers were advised to breastfeed only or exclusively 
for 4 to 6 months than HIV positive mothers (90/100 [90%] vs.9/42 [22 %]; p<0.001), and 
more HIV positive mothers were advised to choose between formula feeds and breastfeed 
than HIV negative mothers (26/42 [62%] vs. 3/100 [3%], p<0.001).  
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After delivery, 141/182 mothers (77%) reported that they received some information or 
counselling on feeding which included just being asked what their feeding choice was, 
being told to start breastfeeding, the advantages of breastfeeding, advice on maintaining 
breastfeeding, or advice on sterilisation of bottles. Thirty six (86%) of mothers who were 
HIV positive reported to have received some form of advice or counselling post delivery 
including just being asked what their feeding choice was.  The majority (93%) of all 
mothers who were counselled post delivery claimed to have received the counselling from 
the nurse or midwife who attended the delivery. 
 
4.8.2 Mothers’ Choice 
During the interview, mothers’ were asked what their feeding choice was before delivery 
and what they had decided to feed the infant after delivery, as well as whether anyone had 
influenced their decision making. Of the HIV positive mothers, 10/42 (24%) decided to 
breastfeed and 29/42 (69%) decided to formula feed during pregnancy and a further 3/42 
(7%) made their choice to formula feed post delivery.  One hundred and twenty four HIV 
negative mothers (89%) decided to breastfeed and 6/140 (4%) decided to formula feed 
during pregnancy. A further 8/140 (6%) and 2/140 (1%) made their decision to breast and 
formula feed respectively, post delivery. Fifty seven mothers (31%) reported that their 
decision was influenced by another person. Health care workers influenced feeding choice 
in more than half of these participants (figure 6). 
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Figure 6: Percentage of mothers whose feeding choice was influenced by another person 
16%
54%
9%
19%
2%
0%
10%
20%
30%
40%
50%
60%
Partner Health care 
worker 
Counsellor Family Other 
P
e
rc
e
n
ta
g
e
 o
f 
m
o
th
e
rs
People influencing mothers feeding choice
 
 
4.8.3 Timing of First Feed 
Less than one-half of mothers (82/182 [45%]) fed their infants within the first hour. The 
majority of infants were fed by their mothers within the first three hours (131/182 [72%]) 
(figure 7). 
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Figure 7:  Time at which infants received their first feed from their mother 
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4.9 Recording of Feeds and Feeding Choice 
Of the 140 HIV negative mothers, 132 (94%) chose to breastfeed, and 8 (6%) chose to 
formula feed. A record of the mother’s feeding choice was present in only 43/140 (31%) of 
the bedletters, of whom 40/43 (93%) selected breastfeeding and 3/43 (7%) formula 
feeding. The infant’s first feed was recorded in 67/140 (48%) of the participants records, 
with almost equal number of infants recorded as being breast (33/67 [49%]) and formula 
fed (34/67 [51%]). (figure 8). 
 
Of the 42 mothers who were HIV positive, 10 mothers (24%) chose to breastfeed and 32 
mothers (76%) selected formula feeds. For only twenty five (60%) mothers, was a record 
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of her feeding choice present in the bedletter, of which 18/25 (72%) selected formula 
feeding and 7/25 (28%) breastfeeding. In the infants’ records there were 28/42 records 
(67%) of the infants first feed, with 22/28 (79%) being formula fed and 6/28 (21%) 
breastfed (figure 8). 
 
Figure 8: Mothers’ feeding choice (verbal) and infant’s first feed (from infant’s record) in 
HIV positive and HIV negative mothers 
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From the formula fed infants’ records it was noted that 27/56 infants (48%) were initially 
fed formula by the healthcare worker. Of those born to HIV positive mothers, 12/22 
infants (55%) who were formula fed were fed initially by the healthcare worker. 
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4.10 Post Delivery Counselling 
Fifty five percent of HIV positive mothers received further counselling after delivery from 
the midwife or nurse in the unit, including counselling on feeding, risk of transmission of 
opportunistic infections. 
 
Seventeen percent (7/42) of HIV exposed infants’ Road to Health Cards had an indication 
that the infant was HIV exposed and in only 3/42 (7%) of cases did their Road to Health 
cards indicate that they were to receive formula milk. 
 
4.11 Interview with the Unit Manager 
The unit managers of each facility were interviewed and asked a series of questions 
regarding the operation of the PMTCT programme. All of the managers reported that their 
unit followed the national PMTCT protocol and all units provided VCT. One facility did 
not provide partner counselling. Counselling at all the units was provided by either a 
counsellor or nurse or midwife; no doctors were involved in VCT. The counselling 
included discussion about the risk of transmission of HIV to the infant, preventing new 
infections in pregnancy, the use of nevirapine, feeding choices, cotrimoxazole prophylaxis, 
and follow up care of mother and infant. Eight units (67%) claimed that they discussed all 
of the above aspects; four units (33%) did not include a discussion on feeding choices 
during antenatal counselling. 
 
4.11.1 Testing 
All 12 units used the rapid HIV testing method and testing was done by nurses or 
counsellors. Results were recorded according to the protocol coding system in all units 
(However, this claim was contradicted during the record review as some units had their 
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own system of coding/ recording results). All managers reported that results were given to 
the mothers immediately after testing, and three units also disclosed results to the mother 
at a later stage if there was some discrepancy with the results, or if the mother preferred to 
be given her results later. Ten units were able to perform CD4 counts once a mother tested 
positive for HIV, the other two units did not have the facilities or the support services to 
carry out CD4 testing on the mothers. 
 
4.11.2 Antiretroviral Therapy  
All 12 units dispensed nevirapine antenatally. Nevirapine was dispensed by the health care 
workers at all units, and in two units counsellors dispensed the medication as well. The 
dispensation of the drug to the pregnant women was recorded in the nevirapine register. 
Only one unit provided mothers with an information leaflet describing the drug and 
indicating when to take the drug.  Seven of the twelve facilities were able to provide 
HAART to those mothers who qualified for it. After CD4 testing was done, those who 
qualified for HAART were referred to that facility’s ARV clinic. Mothers with a CD4 
count less than 200 or clinical category stage C qualified for HAART, based on national 
guidelines at the time.  
 
4.11.3 Labour 
When mothers presented in labour their HIV results were obtained from the antenatal card. 
In the event that there was no result recorded on the card, the result was obtained from the 
results register if the mother booked at the same clinic (8 units), provided that mothers 
presented during the day shift, i.e. before 4pm. If not, mothers would be asked if they were 
aware of their result (6 units) or mothers were counselled and tested after delivery (3 
units). None of the units tested unbooked mothers without results, when they were in 
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labour. Once the mother was established to be HIV positive the health care worker 
attending the delivery was responsible for ensuring that the mother received or took her 
dose of nevirapine at all units, and this was recorded in the mothers’ file according to 
protocol in eight of the twelve units. The subsequent dose given to the infant was recorded 
according to protocol in the mother’s or infant’s file in 9 units, in the maternity or birth 
register in 4 units, in the nevirapine register in 8 units and on the Road to Health Card in 2 
units. 
 
4.11.4 Feeding 
Managers claimed that feeding choices were discussed antenatally and postnatally at all 
units. It was policy that the mother decided on the initial feeding choice and was the first 
to feed the infant except if the mother was extremely ill. The midwife was the first to feed 
the infant in two units and the mother was the first to feed the infant in the other ten units. 
Free formula milk was available at all facilities as part of the PMTCT programme. Only 
one unit manager was not in favour of mothers receiving free formula milk as her personal 
preference was for mothers’ to exclusively breastfed their infants. 
 
4.11.5 Post Delivery Counselling 
Managers at all units claimed that their service provided post delivery counselling which 
included feeding choices, cotrimoxazole prophylaxis, testing infants for HIV, and general 
follow up of infants initially at three days, and then at six weeks for immunisation and for 
HIV testing. Most unit managers (11/12) were aware of the earliest age of testing (6 
weeks), however fewer (8/12) were aware of what test was usually carried out. The three 
unit managers who were unsure of the test carried out, believed that infants were also 
tested by either the HIV Elisa of HIV Rapid test.  The declared reason for their uncertainty 
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was that they themselves were not involved with testing of the infants at six weeks, and 
that at that moment not all facilities were able to provide the service. 
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CHAPTER FIVE 
 
DISCUSSION 
 
5.1 Summary of the Key Findings 
 
All twelve units had a PMTCT programme in place that closely followed the national 
PMTCT protocol according to their managers. There were high overall rates of VCT 
uptake and high acceptance of testing; however disclosure rates of a positive result to a 
partner or someone else were poor.  The rate of nevirapine administration to the mother 
antenatally (for use at the time of labour) was good but actual administration of the drug to 
both mother and infant at the time of birth were disappointingly poor. The mother’s 
preferred choice of feed and the initial feed received by the infant were both poorly 
recorded. Clinic managers provided an inappropriately optimistic perspective of their 
clinics functioning. 
 
5.2 Findings on Aspects of the PMTCT Programme  
 
5.2.1 Entry into the System 
Some 95% of participants attended an antenatal service during their pregnancy. This 
correlates with national figures of antenatal clinic attendance in 2006 of 100%.34 However 
these national figures are an overestimate, with attendance rates across the different 
provinces ranging from 76% in the Eastern Cape to 120% in Kwa-Zulu Natal. The figure 
for Gauteng was 115%. In 2004, the Health Systems Trust reported the national antenatal 
attendance rate as 95.5%.34 
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 Mothers obtain antenatal care from different sectors of the health care system during their 
pregnancy, including from general practitioners (private sector), antenatal clinics and 
hospitals. With the strong influence of traditional health care on African societies, some 
might attend traditional healers during their pregnancy. However, there was low (4%) 
reported usage of the services of a traditional healer during pregnancy by participants, a 
much lower rate than that described by Banda et al in Zambia, where 21% of women 
interviewed reported to have visited a traditional healer in that pregnancy.51 This might 
possibly be a result of a reporting bias on the part of mothers owing to the possible 
displeasure they anticipated revealing this fact may have elicited from the researcher.  
 
5.2.2 Voluntary Counselling and Testing (VCT) 
Only 85% of mothers in the study accepted testing. Nevertheless, this figure is higher than 
that reported by the Department of Health’s National Roll-Out programme (56%) 28 or that 
reported by the Health Systems Trust in 2006/2007 (75%).24 Factors that have been 
reported to influence the rate of acceptance to test for HIV include, the method of testing, 
the availability of counsellors and quality of counselling received, fear of stigma, 
discrimination and chronic illness and unsupportive spouse.30, 33, 52 
 
According to the South African PMTCT protocol, HIV counselling and testing is 
recommended on an opt-in basis as opposed to an opt-out basis.21 The latter approach has 
been shown to improve the uptake of testing for HIV, as in Malawi where antenatal HIV 
testing increased to 95%,25 and in Botswana where  antenatal testing increased to 78%.26  
Walmsley, in her commentary on screening for HIV infection quotes other studies where 
the proportion of women tested increased from 33-74% to 81-88% with the opt-out 
method.53  Jayaraman, et al. in 2003, in a study in Alberta, Canada also showed an increase 
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in the rate of HIV testing by 28% in the month after the opt-out method was adopted.29 In 
the report on the initial evaluation of the national PMTCT pilot programme in 2002, Kwa-
Zulu Natal was the only province where testing had been done on an opt-out basis and 
their rates of testing for HIV was almost double that of the national average.28 Changing 
the national protocol for HIV testing from opt-in to opt-out should contribute to much 
higher rates of testing. 
 
Less than three quarters of participants who had tested antenatally received post test 
counselling. The reasons or barriers to not receiving counselling and the quality of the 
counselling received were not examined in this study. Neither can this study offer 
comment on the availability of counsellors or the quality of counselling. 
 
Bajunirwe, et al. in Uganda in 2005 showed that women whose partners approved of them 
testing for HIV were six times more likely to undertake testing.33 In my study, there were 
only 12% of reported instances where the partner was present at the time of testing, despite 
all but one facility claiming that they offered partner counselling and testing. Promotion of 
partner testing is another area that could improve the uptake of antenatal VCT. 
 
Just over a third of women who tested positive for HIV disclosed their results to their 
partner and 17% disclosed their result to someone else. Disclosing one’s result is known to 
positively impact on the care of the child, possibly by improving support from the spouse 
and improving care for the family.54 Fear of stigma, discrimination and lack of support 
from one’s spouse are the usual reasons for not disclosing one’s result.54 However, the 
poor disclosure rates noted in this study may also indicate that the quality of counselling 
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might not be adequate to provide the mother with sufficient support and confidence to 
overcome these barriers.  
 
5.2.3 HIV Positivity Rates  
The HIV positivity rate in this sample was 23%. This is much lower than what was 
expected - the reported 2007 Gauteng seroprevalence rate was 30.3% 5   A likely 
explanation is that the sample statistic is biased as those mothers who feared disclosure of 
their result to an unknown person (the researcher) or stigmatisation might have chosen not 
to participate.  Thirty mothers refused to participate; if all of these were considered to be 
HIV positive, the sample positivity rate would have been 34%.  This might also be the 
reason for much lower HIV positive rates in the West Rand region (12%), compared to the 
other regions which ranged from 22% to 27%. There were more participants who declined 
participating in the study from the West Rand. There was an impression that the 
participants in that region were less open or more hesitant to discuss issues of PMTCT, 
possibly for fear of stigmatisation.   
 
5.2.4 Recording of HIV Result 
Most mothers’ HIV results (when recorded) were recorded by means of a code, usually 
according to the national PMTCT coding system. The coding system uses a # sign 
followed by a number (usually 1), then the first alphabet of the maternal grandmother’s 
name which is followed by the first alphabet of the mother’s name. The coding system is 
quite complex and requires training for its proper use, and not all staff use the coding 
system correctly. It was introduced to allow communication between health care workers 
while at the same time keeping the mother’s result confidential. However using any coding 
system may actually promote the fear of stigmatisation and discrimination rather than 
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promoting acceptance of one’s status and encouraging awareness. It may also contribute to 
poorer quality of care being delivered, owing to misclassification and misinterpretation.  
  
5.2.5 Nevirapine to the Mother and Infant 
On a positive note, the great majority (89%) of mothers who tested HIV positive received 
nevirapine antenatally, for use during labour. The reasons for the 11% not receiving 
nevirapine antenatally included failure to recognise the mother as being HIV positive. 
Ultimately 33 mothers (79%), received nevirapine in labour (30 of whom took the dose 
given to them antenatally and three received a dose in labour ward).  This percentage is 
similar to Spensley, et al’s multi country study figure of 75%,42 but much lower than that 
reported by Onah, et al. at a south-eastern Nigerian tertiary care facility (98%).43 Though 
the current study’s number was much higher than the national figure of 51.7%,35 it is 
inadequate for optimal prevention of mother to child transmission of HIV. This level of 
coverage would still leave 20% of infants born to mothers at risk of contracting HIV with 
at least 7/100 infants contracting the virus. At a provincial level, this would mean that at 
least 2000 additional HIV infected infants would be expected per annum. The actual 
nevirapine coverage figure would be expected to be still lower as the study estimate did 
not account for those mothers who did not test for HIV but were actually positive. 
 
Nkonki, et al. in their study in the Western Cape looked at reasons for missed opportunities 
in the PMTCT programme. They found that most missed opportunities were health system 
related or personal. The personal factors given were loss of the tablet, forgetting the tablet 
and avoiding collecting the tablet because of denial of their result.39 The health system 
factors  included incorrect information given to the mothers on how to take the tablet and 
health staff not supplying the women with the tablet, both as a result of poor 
66 
 
communication and lack of a locus of responsibility.39 Seven patients in this study also 
reported losing or forgetting the tablet or not having the tablet with them when going into 
labour as they were visiting away from home. The four patients in this study who failed to 
receive nevirapine in labour were the 
result of health system related factors including failure by health staff to accept a mother’s 
verbal report of her positive status, and the failure to test mothers who presented without a 
test result having booked elsewhere or at another province. Patient related factors included 
receiving a dose 48 hours previously when in false labour and presenting too late in labour 
to receive a dose.  Communication problems did not come across as a reason for the health 
system related factors.  
 
Two-thirds of HIV-exposed infants received nevirapine. This is higher than the national 
average  (less than 50%)24 and the rates reported by Spensley, et al. in their multi country 
study (45.6%),42 but much lower than that reported by Geddes, et al. at McCords Hospital 
in Durban (98%)44 and Onah, et al. in Nigeria (100%)43. Health service administration is 
poorer in the study settings in comparison to the latter two studies quoted. These include 
activities such as not identifying mothers who were HIV positive and poor record keeping. 
Since nevirapine administration to the  infant was assessed by identification of any record 
of administration in the infants file, mother’s file or the nevirapine register, it is possible 
that the true rate of administration may be higher than that described here (because of 
failure by health workers to capture the administration of the drug).  
 
Only 57% of mother-infant pairs had a record of nevirapine administration to both mother 
and infant. Once again this low statistic may partially be the result of poor record keeping.  
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Nevertheless, this dismal statistic compares favourably to the DoH report indicating that 
37% of mother-infant pairs received nevirapine country-wide.23 
 
 Albrecht, et al. in 2006 in Lusaka, Zambia, showed that mothers who delivered at home, 
had no high school education, delivered low birth weight infants or who had infants born 
in a tertiary centre with low Apgar scores were all less likely to receive nevirapine.40 
While this study did not include any home deliveries, we identified that infants were more 
likely to receive nevirapine at a clinic than a hospital. Higher rates of nevirapine 
administration to infants at a clinic setting was probably the result of better attention to 
identifying HIV positive mothers there (if for no other reason than that they had fewer 
women to care for) . The poorer rate of nevirapine administration to infants at the hospitals 
may also be the consequence of poorer record keeping (resulting in a false negative). There 
was no difference demonstrated between nevirapine administration to mothers in labour at 
a clinic as opposed to a hospital.  
 
Delvaux, et al. in 2009 at 12 PMTCT sites in Rwanda, showed that mothers who were 
unmarried, less educated, had two or less antenatal visits and those who were offered HIV 
testing after the first antenatal care visit were more likely not to adhere to taking 
nevirapine at the recommended time.55Non-adherence was defined as mother and/or infant 
not ingesting single dose nevirapine at the recommended time or not at all. This study was 
unable to demonstrate any difference in nevirapine administration related to the mother’s 
level of education, employment status or if they were living with their partner.  
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 5.2.6 Infant Feeding and Counselling 
The previous South African PMTCT protocol (2001) recommended that mothers should be 
counselled and given the choice to exclusively breastfeed for six months or formula feed 
where feasible from the beginning.20 Counselling was an ongoing process and feeding 
choices was to be emphasised at each encounter with a health care professional.  Free 
formula was provided by the PMTCT centre.20 In 2006, the WHO infant feeding 
recommendation changed and the new protocol recommended that after extensive 
unbiased counselling, if HIV positive mothers fulfilled the AFASS criteria they should 
exclusively formula feed. If the criteria were not met, mothers were encouraged to 
exclusively breastfeed for the first six months or continue breastfeeding until the AFASS 
criteria were met.3 
 
In 2008, across 29 districts in Botswana, Kenya, Malawi and Uganda, Chopra, et al. found 
that in their observed PMTCT counselling sessions, for only 48% of the time were feeding 
options discussed or mentioned. The only recommended feeding option given to the 
mothers was breastfeeding in 85% of case and formula feeding in 10% of cases. In 60% of 
consultations, no mention of the benefit of early cessation of breastfeeding and early 
weaning was made.47 
 
Just over three-quarter of all mothers in this study reported to have received counselling on 
feeding during their pregnancy. We did not assess the quality of the counselling they 
received. Of the HIV positive mothers, more than a third were directed (rather than 
counselled based on individual circumstances) to use either breastfeed or use formula. 
Based on the reported evidence, it is possible that up to 40% of mothers received 
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inadequate or inappropriate advice. The quality of the counselling provided at health 
services requires auditing and monitoring. 
 
Onah, et al. at a tertiary facility in Nigeria, reported that 98.9% of their mothers received 
infant feeding counselling which is a more acceptable figure. However, all their mothers 
chose breast-milk substitutes for their infants. This suggests a bias in the counselling the 
mothers were provided, unless the setting was extremely under-resourced.43 
 
Most mothers had made their feeding choice during their pregnancy with 76% of all HIV 
positive mothers choosing to formula feed. Of the HIV negative mothers 94% chose to 
breastfeed which is reassuring. According to the mothers’ report more than half of the 
mothers feeding choices were influenced by a healthcare worker, indicating the importance 
of the health care workers opinion to the mother, and thus the need for adequate unbiased 
counselling to be offered in the ordinary antenatal programme. 
 
Irrespective of the mother’s choice, there were significant differences in what the first feed 
that the infant received was. With the HIV negative mothers a record of the infants first 
feed was recorded for less than one-half of cases, with equal numbers of infants being 
breast or formula fed. This is unacceptable and a cause for concern. In most local hospitals 
it is standard practice to take the infant to the nursery for routine procedures and 
examination while the mother undergoes the third stage of labour. Infants are often fed 
formula during this period while awaiting transfer to the mother. Infants who are ill are 
reviewed by the paediatric team and may be admitted to neonatal unit if necessary. In such 
cases infants might receive formula from a health worker as the initial feed. 
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Apart from improving the bonding between mother and infant, early skin to skin contact 
has a positive effect on continuing breastfeeding at one to four months, maintaining the 
newborns temperature in the thermo-neutral zone, reducing the infants crying and has 
effects on stabilizing the infants glucose.56 
 
Recording of feeding choices was poor. HIV negative mother’s choice of feed was 
recorded for 31% of the mothers and 48% of the infants’ first feeds were recorded. With 
the HIV positive mothers, the mothers feeding choice was recorded for 60% of the 
mothers, 67% of infants’ first feeds were recorded, with 79% of infants being formula fed. 
 
It is concerning that less than half of the mothers had fed their infants within the first hour 
of life, and just about three-quarters of infants were fed their first feed within the first three 
hours of life. This is contrary to one of the ten recommended Baby-Friendly steps, that is 
to initiate breastfeeding within the first half hour of birth.57 Based on records, 48% of all 
formula fed infants and 55% of formula fed infants who were born to HIV positive 
mothers received their first feed from a health care worker. This is probably as a result of 
hospital protocol and procedures as mentioned above. This is a clear violation of the Baby-
friendly code. Breastfeeding within the first hour has also been shown to reduce the rates 
of sepsis in newborn infants.58 
 
Half of the HIV positive mothers received further counselling after delivery. All of them 
received information about the risk of transmission and the need for prophylaxis, 
cotrimoxazole prophylaxis and testing the infant for HIV.  However, on the infant’s Road 
to Health Cards in only 17% of cases was there an indication that the infant was exposed to 
HIV, contrary to the national coding system which demands that a code to indicate that the 
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infant is exposed should be transcribed on every Road to Health card. In 7% of cases there 
was a specific milk code transcribed indicating that the infant was eligible for free formula 
milk. In none of the cases was there any indication for the need for cotrimoxazole 
prophylaxis charted, as is required according to the national protocol.  
 
Failure to record these probably arises out of health workers fear of the patient being 
stigmatized but is also as a result of protocol not being carried out correctly. This impacts 
on the care of the infant where he/she might only be diagnosed once he presents at a 
facility and requires admission, which impacts on the management he/she receives. The 
diagnosis might also be overlooked in a well child attending a facility for a well infant 
(immunization) visit, where infection might not be suspected and therefore the opportunity 
for opportunistic infection prophylaxis and nutritional support missed. 
 
5.3 Interview with Unit Managers 
 
Although all units claimed to follow the national PMTCT protocol, the interviews with the 
unit managers highlighted a few concerns. A third of the units for instance did not include 
any discussion on feeding options in their initial VCT counselling. Only after a mother had 
tested and was found to be HIV positive were feeding options discussed; thus HIV 
negative mothers were denied information on the benefits of breastfeeding. 
 
Some units had designed their own methods of recording the mothers HIV results, though 
they were all familiar with the national PMTCT coding system. This poses a problem 
where a mother might not deliver at the same facility that she booked at, and thus her HIV 
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status is not recognized, resulting in a missed opportunity to prevent mother to child 
transmission of HIV.   
Nevirapine was dispensed at all units and no record of shortages of the drug was reported. 
One unit provided the mothers with pamphlets with information on the purpose of the drug 
as well as when to take the drug. While this practice should be encouraged to improve 
adherence to taking nevirapine, this study could not demonstrate that it made a difference. 
Most mothers reported that they were offered adequate information on when and how to 
take the drug. 
 
If mothers presented in labour without a HIV result recorded on the antenatal card, most 
units were able to obtain the mothers’ HIV result from clinic registers during working 
hours if the mother had booked at the same clinic. However, if the mother had booked 
elsewhere or presented without an HIV result, apart from the mother disclosing her result, 
the result could only be obtained post delivery. This conforms to the national protocol that 
recommends that testing only take place post delivery in such instances. This, however, is 
less than satisfactory as it only allows only for post exposure prophylaxis to be 
administered to the infant, and misses a vital opportunity to reduce the transmission 
burden.  
 
All unit managers reported that feeding choices were discussed with mothers both 
antenatally and postnatally. This was not confirmed in our interview with the mothers as 
just over three-quarter of mothers reported to have received some information on feeding 
antenatally and postnatally.  
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Two unit managers admitted that infants received their first feed from the health care 
worker due to unit protocols and procedures. However, in this study 44% of recorded 
infant feeds were from a health care worker, which is more than would be expected if only 
two units had adopted that policy. The other units reported that health care workers fed 
infants if mothers were too ill, but this study excluded mothers who were too ill to be 
interviewed. 
 
Free formula milk was available at all units and there was no report of shortages of supply. 
All except one unit manager were in favour of HIV-exposed infants receiving formula 
milk for six months. Health care workers strongly influenced the mother’s feeding choice 
(in 54% of cases). 
All twelve unit managers reported routine follow up of infants at 3 days and then at six 
weeks at which time testing of the infant took place and cotrimoxazole prophylaxis was 
commenced. The validity of these claims could not be tested in the study. 
 
 
 5.4 Limitations of the Study 
 
The study had a number of limitations as outlined below: 
 
Study design 
1. The study sites were chosen by convenience rather than random sampling. Four out 
of the five regions in Gauteng were chosen based on ease of travel and time 
constraints. This limits generalisability of the study findings to the whole Gauteng 
PMTCT population. Nevertheless, it is unlikely that different clinics, hospitals and 
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regions in the province are likely to display major differences in PMTCT 
performance from that described in the study, particularly as an attempt was made 
to include the correct proportion of MOU and hospital deliveries. 
2. Owing to time constraints the sample size had to be limited. A larger sample would 
have improved the confidence limits around the study statistics. 
 
Bias 
1. Clinics and hospitals were informed in advance about the visit and the exact dates 
of the visit. This might have biased the staff to improve on practices such as 
nevirapine administration, record keeping and initiated a protocol review by the 
unit manager. However, this is unlikely to have occurred, in the researcher’s view. 
2. Records or interviews may inaccurately reflect actual practice. The participants 
may have been inclined to please the interviewer and report personal behaviours 
and health worker practices that were untrue (positive bias). Alternatively, poor 
record keeping negatively biases reported coverage, since good practices such as 
nevirapine administration may have occurred, but were simply not recorded. The 
researcher tried to compensate for both these biases, by encouraging participants to 
honestly report behaviours and attempting to review records as thoroughly as 
possible.       
3. Mothers who were actually HIV positive may have chosen not to participate in the 
study, thus reducing the HIV seroprevalence in this sample of patients, while also 
biasing conclusions. This situation is considered to have been quite likely.  
4. This study could not identify possible HIV positive mothers in the group of 
patients who had not tested for HIV or refused to reveal their status. This may have 
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unduly inflated the true nevirapine coverage statistics, i.e. the situation appears 
better than what it really was. 
 
  
 5.5 Further Research Questions 
• Could replacing the coding system, with a more open description of HIV status 
improve identification of HIV positive mothers? 
• Can opt-out VCT succeed in South African settings?  
• Can the implementation of testing mothers for HIV in early labour, for those who 
present without a recorded HIV test result, improve PMTCT of HIV?  
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CHAPTER SIX 
 
CONCLUSION 
 
This study emphasises that the quality of the PMTCT programme needs revising and the 
quality of ongoing support and care received needs improvement. Some even argue that a 
more complex regimen, involving introduction of antiretrovirals earlier in pregnancy and 
more drugs, improves adherence and reduces the number of missed opportunities.39 
 
Emphasis needs to be placed on improving the number of participants entering into the 
programme by improving the number testing for HIV, recognising both positive mothers 
and exposed babies, improving the counselling on feeding choices and providing ongoing 
support and incorporating PMTCT programmes into mother and child health services. 
Families need to receive ongoing health and social support and measures must be 
introduced to ensure that they do not fall through the cracks in the present system.  
 
As of February 2008, PMTCT facilities around the country began implementing the new 
national PMTCT programme, with improvements on many aspects of the previous 
programme, the most remarkable being the introduction of dual antiretroviral therapy for 
both the mother and baby. While improving the antiretroviral regimen will reduce the 
transmission of HIV from mother to child, there are still many problems along the different 
steps in the PMTCT cascade that need to be improved on, as described in this study. 
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Recommendations 
1. Each region (district) and sub-district, including its associated hospitals and clinics, 
should set explicit PMTCT targets, for areas such as VCT coverage, nevirapine 
administration to mother, nevirapine administration to infant, feeding options for 
the mother and follow up care of infant and mother with infant testing at six weeks 
of age. The achievement of these targets must be monitored by the sub-districts, 
districts and province. Well functioning health centres should be rewarded, while 
underachieving centres should be supported, and if necessary reprimanded. The 
underlying principle is that there has to be accountability.   
 
2. There has to be clear responsibility for the implementation of PMTCT programme 
within the different service levels. Thus, at the provincial level the role of the HIV, 
AIDS and Sexually Transmitted Diseases (HAAST) and Maternal and Child Health 
(MCH) directorates in managing the programme, including how they co-operate, 
needs to synchronised. Similarly, integration of the antenatal and child health 
services needs to be developed and supported at district level.  
 
3. In addition to the ordinary monitoring and evaluation activities, the health care 
manager in charge of the PMTCT programme at each facility needs to conduct 
regular unplanned audits on the different components of the PMTCT programme, 
using a standard guideline or drawing up a checklist based on the present national 
programme recommendations. Audits on the quality of counselling, testing, post-
test counselling, drug dispensing, feeding choices, post delivery counselling and 
ongoing follow up should be done at irregular, but frequent, intervals to prevent 
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expectation of the audit by staff. An external (provincial) auditor should be 
allocated to audit each district. 
 
4. Regular in-house, in-service training and updates needs to take place at all facilities 
to update staff on changes to the programme and to reinforce present polices to 
ensure effective running of the programme.  
 
5. Those involved in antenatal counselling of mothers should undergo regular training 
to improve their skill. Counsellors should be provided with a support service for 
themselves. 
 
6. The Department of Health needs to adopt and implement the opt-out method of 
testing as part of the national protocol, to increase the number of mothers testing 
for HIV. 
 
7. Partner counselling rates need to be improved. Although eleven of the twelve 
facilities provided partner counselling and testing, only 12% of partners were tested 
in this sample. Apart from the counselling received at an antenatal visit, partners 
need to become more aware of the need for PMTCT of HIV. NGOs promoting HIV 
testing and treatment can assist by including questions about partners: “Is your 
partner pregnant? Have both of you tested for HIV? What about your baby?” as 
part of their health communication strategy. 
 
8. Identifying mothers who are HIV positive must be standardised and simplified. The 
coding system presently used can be incorrectly used and results misinterpreted if 
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one is not trained to use the table. A suggestion is to include on the antenatal card a 
section on PMTCT, as follows (Table 4): 
 
Table 4: Suggested method of recording mother’s HIV result and relevant PMTCT data on 
the mother’s antenatal card 
 PMTCT:   (Circle the relevant blocks)               
HIV Result + _ 
CD4 Count Date:   Date 
Eligible for HAART Yes  No 
Dual Therapy Yes No 
 Date started: 
Nevirapine only Yes  No 
Feeding Counselling 
received  
Yes  No 
Feeding Choice  
AFASS criteria met? Yes No 
 
 
9.  Mothers who present in labour without evidence of a HIV result, must have a rapid 
test performed immediately and offered nevirapine if appropriate, provided the 
mother is in the first stage of labour. The opt-out system will assist here as well, as 
the test done would be part of “routine blood taking”. Mother’s declaration of their 
positive status, even in the absence of documented evidence of this, should be an 
indication for providing antiretroviral prophylaxis during labour. 
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10. The labour ward admissions file, which is a standardised file used by clinics and 
hospitals for mothers admitted in labour, needs to also include a specific section 
(perhaps on the inner aspect of the front cover of the file) indicating the mothers 
status, her antiretroviral regimen antenatally, the antiretrovirals used in labour and 
antiretrovirals administered to the baby and choice of feeding. A suggested format 
is presented below (Table 5): 
 
Table 5: Suggested method to document PMTCT data in labour admissions file 
PMTCT:   (Circle the relevant blocks)               
HIV Result + _ 
CD4 Count Yes  No 
HAART Yes  No 
Dual Therapy Yes No 
 Date started: 
Nevirapine only Yes  No 
AZT in labour Yes No 
Nevirapine in labour Yes No 
Nevirapine to baby Yes No 
AZT to baby Yes No 
Feeding Counselling 
received  
(post delivery) 
Yes  No 
Feeding Choice  
AFASS criteria met? Yes No 
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11. All those involved in post delivery counselling must undergo regular training to 
practice unbiased counselling on feeding as well as counselling mothers on follow 
up care.  Unless a mother fulfils the AFASS criteria, they should be encouraged to 
breastfeed.  
 
12. Facilities, mostly hospitals, where mothers and babies are separated soon after 
birth, need to be pressurised by health authorities into changing this policy. Except 
where a mother is too ill or has received a general anaesthetic, all babies must be 
fed by their mother in the first hour of life. Adoption of the ten baby-friendly steps 
will go a long way to achieving this. 
 
13. Documentation of the mothers feeding choice and the babies first feed must be 
compulsory for both the mother’s and the baby’s health service record to ensure 
that mixed feeding practices do not commence at health centres. 
 
14. Identifying HIV exposed infants must also be simplified. The easiest method would 
be to document this on the Road to Health Card (RTHC) which is the present 
recommendation, however this is seldom done and mothers are also not counselled 
on when their babies need to be tested nor on the need for cotrimoxazole 
prophylaxis. The Road to Health Card needs to be modified as well to include a 
section on PMTCT, either by including it on the present card system or changing it 
to the booklet form used in other countries such as Botswana. The following is a 
suggested table to include on the RTHC (Table 6): 
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Table 6: Suggested table to include on the Road to Health Card to indicate PMTCT 
information 
PMTCT:   (Circle the relevant blocks) 
Is infant exposed? Yes No 
Received nevirapine Yes No 
Received AZT Yes No 
 How long? _________days  
Feeding Breast Formula 
PCR testing Date:______________ Where? _______________ 
Bactrim prophylaxis When to start? _____________ 
 
15. PMTCT services needs to be integrated into existing paediatric and maternal health 
care services. It would be best for the mother to attend one facility for herself and 
her child as this would improve follow up and would cost the mother less to attend 
on one day than on different days. An ideal situation would be one where the 
follow up service occurs at the same place as antenatal clinic, however this is not 
the situation at most facilities, as these facilities have their own HIV units for 
paediatrics and adults. An adequate referral system post delivery must be in place 
at every unit where mothers would be given the same follow up dates for both 
herself and her baby, to ensure that they both achieve and retain optimal health. 
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APPENDIX A  
 
 
PART ONE: INTERVIEW WITH MOTHER: 
 
Note highlighted questions refer only to participants who are HIV positive. 
 
Date:___/__/2006 
 
Study no: _____________________ 
 
Hospital/Clinic:__________________ 
 
Demographics 
 
I would like to start by asking you some questions about yourself 
1. How old are you?  
2.  What is your marital status?    1=unmarried  
2=married, traditional 
3=married, legal   
4=widow 
5=divorced 
6=separated 
9=other             
3. How many children do you have?  
4. Have any of your children passed away? 
If yes, how many?        
1=No      2=Yes 
5. What is your highest level of education? 
If school, write actual grade:_________ 
1=None 
2=primary school 
3=secondary school 
4=tertiary education 
6. Are you working?                       1=No      2=Yes 
7. Is your partner working? 1=No      2=Yes 
8. Where do you live? 
(Town/township name: ____________________) 
1=In Gauteng 
2=Outside Gauteng 
9. Do you live with your partner? 1=All the time 
2=Most of time 
(>50%) 
3= Some of the time 
(20-50%) 
4= No 
 
 
 
 
Antenatal visits 
 
I now want to ask you about the care you received while you were pregnant 
 
a) Did you visit any of the following? 
If yes to any, then ask the following: 
b) At what stage of your pregnancy (weeks)? 
c) Were you offered counselling (advice) about HIV at any of the visits? 
d) Were you offered an HIV test? 
e) Did you choose to have the test? 
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  A B C D E 
20.    General practitioner 
(GP) 
1=no 2=yes  1=no 2=yes 1=no 2=yes 1=no 2=yes 
21. Traditional healer 1=no 2=yes  1=no 2=yes 1=no 2=yes 1=no 2=yes 
22. Antenatal Clinic 1=no 2=yes  1=no 2=yes 1=no 2=yes 1=no 2=yes 
23. Hospital 1=no 2=yes  1=no 2=yes 1=no 2=yes 1=no  2=yes 
 
If answer yes to any of c, d or e above continue. If no, go to Q30 
 
24. When you received VCT was your 
partner with you at the time 
1=no  2=yes 
25. 
 
 
Are you aware your HIV result? 
(please do not tell me the result) 
If no, why not? (proceed to Q30) 
1=no  2=yes 
26. Who gave you your result? 
 
 
1=nurse 
2=clinic doctor 
3=GP 
4=counsellor 
9=other 
27. When did you receive the result? 
 
 
1=immediately after VCT 
2=follow up visit 
3=admitted in labour 
9=other 
28. Did you receive any further 
counselling (advice) at the time you 
got your HIV result (post test 
counselling)? 
 
1=no   2=yes 
29. Have you told your result to your 
   (i) partner or  
   (ii) anyone else? 
 
1=no   2=yes 
1=no   2=yes 
 
 
30. Do you know what Nevirapine is? 1=no   2=yes 
30a 
 
 
 
30b 
If yes, please tell me what it is? 
 
 
 
Researcher code: acceptable 
 
 
 
 
1=no   2=yes 
31. Did you or your baby receive 
Nevirapine? 
If no, proceed to Q 36 
1=no   2=yes 
32. Were you given Nevirapine to take 
home when you were pregnant? 
1=no   2=yes 
33. Were you told when to take the 
Nevirapine?     
1=no   2=yes 
 
34. What were you told?         
 
35. Who gave you this information?     1=nurse      
2=clinic doctor 
3=GP 
4=Instruction sheet/ Pamphlet 
5=Other mothers 
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9=other 
36. Did you receive any counselling about 
the feeding of your baby while you 
were pregnant? 
If no, continue to Q38 
1=no   2=yes 
37. What were you told? 
 
 
 
 
Labour Ward 
 
I now want to ask you some questions about your labour and delivery 
38. When you went into labour which 
clinic or hospital did you go to? 
1=this clinic 
2=another clinic 
3=this hospital 
4=another hospital 
5=at home 
9=other 
39.  Where was your baby born? 1=this clinic 
2=another clinic 
3=this hospital 
4=another hospital 
5=at home 
9=other 
40. How was your baby delivered? 1=normal vaginal delivery 
2=assisted delivery 
3=caesarean section 
41. Did you take Nevirapine when you 
were in labour? 
If no, proceed to Q41 
If yes, proceed to Q42 
1=no   2=yes    
 
42. Why not? 1=forgot tablet 
2=lost tablet 
3=did not receive tablet  
9=other 
43. When did you take the Nevirapine?          
44a.  Was the Nevirapine tablet that you 
took, the one given to you at the 
antenatal clinic / during your 
pregnancy? 
1=no   2=yes 
44b. Was the Nevirapine tablet that you 
took, the one given to you when you 
were in labour? 
1=no   2=yes 
45. Did the midwife ask you if you had 
taken nevirapine in labour? 
1=no   2=yes 
46. Did you tell the midwife that you had 
taken the tablet? 
1=no   2=yes 
47. Did you take Nevirapine before at any 
time before, for example if you had 
labour pains at an earlier time? 
If no, proceed to Q48 
1=no   2=yes 
48.  How many tablets?  
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Post delivery 
 
I now want to ask you some questions about what happened after your baby 
was born 
 
49. Do you know if your baby received 
Nevirapine? 
If no, proceed to Q50 
1=no   2=yes 
50. How do you know this for sure? 
 
                             
1= Enquired from staff 
2= Was informed by staff           
3= Was informed by counsellor 
4= Looked through file 
9= other 
51. 
 
 
 
51a 
 
 
 
 
 
Did you receive any counselling after 
your baby was born? 
If no, proceed to Q54 
 
Did you receive any counselling/after 
the baby was born about:  
a) how best to feed your baby (your 
choices ) 
b) bactrim prophylaxis 
c) testing your baby for HIV 
1=no   2=yes 
 
 
 
 
 
1=no   2=yes 
 
1=no   2=yes 
1=no   2=yes 
51b Did you receive any counselling/advice 
after your baby was born about how 
best to feed your baby? (your choices) 
 
1=no   2=yes 
52. Who counselled you? 
  
 
1=midwife/nurse 
2=doctor  
3=counsellor 
9=other 
 
53. When were you counselled? 1=immediately after delivery 
2=within one hour of delivery 
3=within three hours of delivery 
4=within six hours of delivery 
5=within 24hours of delivery 
6=24-72 hours after delivery 
9=other 
54. Where were you counselled? 1= labour ward                         
2= postnatal ward 
9= other 
 
55. 
 
How long after your baby was born did 
you first see your baby? 
 
1= immediately 
2= less than one hour 
3= one to three hours 
4= more than three hours 
5= more than 24 hours 
6= more than two days 
9=other 
56. How long after birth did you first feed 
baby? 
If answer to Q55 is 1 or 2 proceed 
to Q57, if not then 
        
1= within the first hour     
2= within 3 hours      
3= within 6 hours     
4= more than 6 hours 
5= more than 24 hours 
9=other 
57. Do you know if baby was fed before 1=no    2=yes 
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this? 
If no, proceed to Q58 
58. What was baby’s first feed? 
        
1= breast milk               
2= formula milk 
3= unsure 
9= other 
59. What have you decided to feed your 
baby? 
        
1= breast milk 
2= formula milk 
3= unsure 
9= other 
60 If answer to Q58 is 2, Where will you 
get milk from? 
1=buy milk 
2=from clinic 
3=from hospital 
9=other 
61. When did you decide what you are 
going to feed your baby? 
1= before birth     
2= after birth 
62. Did anyone help you to make this 
decision? 
If no, proceed to Q63 
1=no   2=yes 
63. Who? 1=partner 
2=health care workers 
3=counsellors 
4=family members 
9=other 
64. Do you know when to take/bring your 
baby back to clinic for “check up”?                    
1=no   2=yes 
 
65. Have you been given a Road to Health 
Card for your baby? 
1=no   2=yes 
66. Should your HIV status be reflected on 
the baby’s Road to Health card? 
a) If yes, what should it say? 
b) If no, why not? 
1=no   2=yes 
67. Has the clinic or hospital told you 
anything about free formula milk 
being available for some babies? 
If no, go to Q68? 
1=no   2=yes 
68. 
 
69. 
What have they told you? 
 
Do you think that some babies should 
be offered free milk? 
If yes, which babies should receive 
free milk? 
 
     
 
1=no   2=yes                
 
Thank you very much for your time and help. 
Do you have any questions for me? 
Please accept this present from me. 
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PART TWO; SECTION A; MOTHERS RECORDS: 
 
Study Number: ________________ 
 
Date: _____/___/2006 
 
Hospital/Clinic: ____________________ 
101. Age  
102. Parity/Gravidity: P      G 
103. Date of delivery: ___/___/2006 
104. Antenatal Card present in file:    
If no, proceed to Q106                                                                                                      
1=no   2=yes 
105a  Where booked?   
105b How many antenatal visits?  
106 Record of VCT:  
Date pre test counselling received:                  
Date post test counselling received:  
 
___/___/2006 
___/___/2006 
107. When was HIV test done: 
      
1=antenatally  
2=labour ward admission    
3=postnatally 
9=other 
108. What is the result of the test?                                                        
 
1= positive          
2= negative             
3= unknown/ no result 
109. How is result recorded? 1= Code              
2= Marked as positive or negative      
3= Not recorded 
9= Other 
110. Where is result recorded? 1= Antenatal card     
2= File                 
3= Admission form 
4= Not recorded 
9= Other 
111. Record of Nevirapine/HAART given to 
mother? 
1=no   2=yes 
112. Record of CD4 count present? 1=no   2=yes 
113. Record of post delivery counselling 
by any health care worker or 
counsellor to mother? (about 
anything) 
If no, proceed to Q115 
1=no   2=yes 
114. Was the following discussed? 
a)Risk of transmission and need for 
prophylaxis                            
b)Feeding choices                                                  
c)Bactrim prophylaxis                             
d)Testing baby For HIV                                                
 
1=no   2=yes 
 
1=no 2=yes 
1=no   2=yes 
1=no   2=yes 
115. Record of mother’s choice of feeding?                                                       1=no 2=yes
116. What is mother’s choice recorded as? 1=Breast milk          
2=Formula milk           
9=Other 
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SECTION B: BABY’S RECORDS 
 
Study No: _________________ 
 
Date:  _____/____/2006 
 
Hospital/Clinic: ________________ 
 
201. Hospital No  
202. Date of Birth  
203. Gestational Age 
(_____ weeks) 
1=term 
2=preterm 
204. Weight (g)  
205. Apgar score at 1 minute  
206. Apgar score at 5 minute  
207. Clinical Condition of Baby 1=well (with mother)        
2=ill (admitted to neonatal 
unit) 
3=very ill (high care/NICU) 
208. Reason for admission 1=respiratory distress (non-
term)   
2=birth asphyxia    
3=preterm 
4=sepsis       
5=surgical        
6=congenital abnormality     
9=other 
209. Where are baby’s details being obtained 
from?   
1=mother’s file                    
2=neonate admission file 
3=newborn clinic card 
4=Road to Health card 
9=other 
210. Record of mother’s HIV result present? 1=no    2=yes 
211. Is answer to Q210 no, then 1=awaiting result       
2=refused testing     
3=not yet tested 
4=not recorded 
212. Record of Nevirapine administered to baby             
If yes, when administered 
1=no   2=yes 
Date:___/___/____ Time: 
213. Record of baby’s first feed? 1=no   2=yes 
214. What was baby fed? 1=Breast milk          
2=Formula milk             
9=Other 
215. Who fed baby initially? 1= Health care worker      
2= Mother 
216. Is a Road to Health Card available? 1=no   2=yes 
217. If answer to Q217 yes, AND baby HIV 
exposed, does Road to Health Card indicate 
a) Exposure                                               
b) nevirapine given                                           
c) milk code                                                                        
d) due for bactrim prophylaxis                   
 
 
1=no   2=yes 
1=no   2=yes 
1=no   2=yes 
1=no   2=yes 
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APPENDIX C 
 
 
PART THREE: 
REVIEW OF CLINIC OR HOSPITAL NEVIRAPINE REGISTER FOR 
BABY’S DOSE 
 
Study No: ___________ 
 
Date: ___/____/2006 
 
Hospital/ Clinic: ____________ 
 
301. Where are records of Nevirapine 
administration to baby found? 
  
1=birth register           
2=maternity register  
3=nevirapine register 
302. Is baby’s hospital number present in 
register? 
1=no   2=yes 
303. Is mothers hospital number present in 
register? 
1=no   2=yes 
304. Is mother’s HIV result recorded in 
register? 
1=no   2=yes 
305. How is the mother’s result recorded 1=code 
2=marked as positive or negative 
9=other 
306. Is the dose of Nevirapine administered 
to baby recorded? 
1=no   2=yes 
307. Is the name of the person who gave 
the dose recorded? 
1=no   2=yes 
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PART FOUR:  
FUNCTIONING OF HEALTH SERVICE SYSTEMS; 
INTERVIEW WITH UNIT MANAGER 
 
Hospital/Clinic: ______________ 
 
401. What protocols available for your hospital/clinic’s PMTCT programme? 
 
 
402. Who is responsible for ensuring that the programme runs effectively? 
 
 
403. Is VCT offered at your clinic/hospital 1=no   2=yes  
 
404. Is partner counselling offered at your 
clinic/hospital? 
1=no   2=yes 
405. Is counselling offered: 
a) antenatally 
b) in labour 
c) postnatally 
 
1=no   2=yes 
1=no   2=yes 
1=no   2=yes 
 
406. 
 
Who provides the counselling? 
   
 
1= counsellors                   
2= nurses/midwives 
3= doctors 
9= other 
407. Where does counselling take place? 
408. What does pre-test counselling 
include:  
    
1=risk of transmission of HIV 
from mother to baby? 
2=preventing new infections 
during pregnancy? 
3=the use of Nevirapine 
4=feeding choices 
5=bactrim prophylaxis 
6=follow up care of mother and 
baby 
409. Who performs HIV test on mother? 1=nurses/midwives      
2=counsellors 
3=doctors 
9=other 
410. What method of testing is used? 1= HIV rapid test 
2= HIV Elisa 
411.  When are the results given to the 
mother?  
1= immediately 
2= follow up visit 
412. Who gives the results to mothers? 
   
1=nurses/midwives      
2=counsellors 
3=doctors 
9=other 
413. How are the results recorded? 
   
1= Code     
2= positive/negative       
3= other 
414. Where are the results recorded? 
  a= clinic register 
  b= antenatal card 
 
1=no   2=yes 
1=no   2=yes 
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  c= admission file 1=no   2=yes 
415. Is Nevirapine issued to mother 
antenatally? 
1=no   2=yes 
416. When?  
417. Who dispenses the Nevirapine to the 
mother? 
 
1=health care workers     
2=counsellors 
9=other 
418. What information is given to the mother? 
 
419. Does mother receive some form of 
information leaflet with the drug? 
1=no   2=yes 
420. Where is the dispensing of drug recorded? 
421. Are CD4 counts done after testing for 
HIV? 
1=no   2=yes 
422. Does your facility provide HAART to 
pregnant mothers? 
1=no   2=yes 
423. Who qualifies for HAART? 
 
424. When mothers present in labour, how is the mother’s HIV result 
established? 
425. What is done if there is no record of mother’s result on the antenatal card? 
 
426. Who is responsible for ensuring that Nevirapine was given to the mother? 
 
427. When is Nevirapine given? 
 
428. Where is the dose of Nevirapine 
recorded? 
1=mother’s file 
2=nevirapine register 
9=other 
429. Who is responsible for giving Nevirapine to the babies? 
 
430. Where is the dose of Nevirapine given 
to the baby recorded? 
    
1=mother’s/baby’s file 
2=birth register/maternity           
    register 
3=Nevirapine register 
4=RHC Card 
9=other 
431. Are feeding choices discussed with the 
mother antenatally? 
If no, proceed to Q434 
1=no   2=yes 
432. By whom? 
433. When? 
434. Are feeding choices discussed with the 
mother postnatally? 
If no, proceed to Q437 
1=no   2=yes 
435. By whom? 
436. When? 
437. Who makes the decision about what the baby’s first feed will be? 
 
438. What if the mother is too ill? 
 
439. Who gives the baby its first feed? 
 
1=nurse/midwife 
2=mother 
9=other 
440.  What is the baby fed routinely for its 
first feed? 
1=breast milk 
2=formula milk 
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9=other 
441. Is free formula milk (as part of the 
PMTCT programme) available at your 
clinic/hospital? 
1=no   2=yes 
441. Who qualifies for free PMTCT formula milk? 
 
442. Are you in favour of baby’s of HIV positive mothers being offered free 
formula milk for six months? 
 
443. When are mothers told to bring their babies back for first “check-up”? 
 
444. At what age are infants first tested for HIV? 
 
445. What test is performed? 
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APPENDIX E 
 
ETHICAL CLEARANCE 
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APPENDIX F 
 
 
A DESCRIPTIVE STUDY OF ASPECTS OF THE PREVENTION OF MOTHER 
TO CHILD TRANSMISSION OF HIV PROGRAMME AT SELECTED 
HOSPITALS AND CLINICS IN GAUTENG 
 
 
INFORMATION SHEET AND INFORMED CONSENT FOR PARTICIPANTS 
 
Hello, 
 
I am Dr Farrah Ismail, a doctor in the Department of Paediatrics and Child Health at the 
University of Witwatersrand.  I am presently carrying out a study on the Prevention of 
Mother to Child Transmission of HIV Programme in Gauteng. 
 
I would like you to read this information sheet to understand what is involved in this study. 
 
Why am I doing this study? 
To assess whether the programme is running properly and to find out if there are any 
problems with the programme that we can try and fix. 
 
What do we expect from the participants of this study?  
You are invited to participate in this study. It is completely voluntary meaning that you can 
decide whether you want to talk to me or not. I am asking all mothers who have delivered 
babies at this clinic/ hospital to take part in this study, irrespective of whether they are HIV 
positive, HIV negative or if they do not know their HIV result. 
 
What do I expect from you if you agree to take part in the study? 
I will be asking you 67 questions about the care you received during your pregnancy 
(including voluntary counselling and testing for HIV), what medicines you received during 
labour (specifically the medicine called Nevirapine) and how you are feeding your baby. 
This should not take longer than 30 minutes. 
 
I am also requesting to look through your file and antenatal card.. 
 
May I withdraw from the study? 
Your participation in this study is completely voluntary and you may withdraw from the 
study at any time. You can choose not to answer any question I ask that you do not wish to 
answer. If you withdraw or choose not to participate this will not affect the care you 
receive in this ward. 
 
What about confidentiality? 
Whatever I discuss with you or read in your file will remain confidential. This means that I 
will not tell or discuss this with anybody else. I will only record your study number on my 
question paper. No records will be kept of your name, address or any other personal 
details. 
 
Should there be anything on this sheet that you do not understand, please ask me to explain 
the words or information to you.  
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I will not receive any direct benefits from doing this study. 
 
If you are unhappy to participate in this study please inform me and I will leave. This will 
have no effect on your or your baby’s care in the ward. 
If you are happy to participate please read and sign the attached consent form. 
 
If you have any queries afterwards you may contact me at (011) 481 5196, or you may 
contact the chairperson of the Human Research Ethics Committee at the University of 
Witwatersrand, Prof Cleaton-Jones at (011) 717 2229. 
 
Thank you 
 
 
Dr F Ismail 
Department of Paediatrics and Child Health 
University of Witwatersrand  
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APPENDIX G 
 
A DESCRIPTIVE STUDY OF ASPECTS OF THE PREVENTION OF MOTHER 
TO CHILD TRANSMISSION OF HIV PROGRAMME AT SELECTED 
HOSPITALS AND CLINICS IN GAUTENG 
 
INFORMATION SHEET FOR THE MANAGER OF THE PMTCT PROGRAMME 
 
Good Day Sir/Madam 
 
I am Dr Farrah Ismail, a registrar in the Department of Paediatrics at the University of 
Witwatersrand. I am currently carrying out a research study describing the delivery of 
prevention of mother to child transmission of HIV programmes (PMTCT) at selected 
hospitals and clinics in Gauteng. My supervisor is Professor Haroon Saloojee. 
 
Why am I doing this study? 
I am doing this study to assist in improving the effectiveness of the programme in 
delivering Nevirapine to babies born to mothers who are HIV positive 
Your Midwife Obstetric Unit(MOU)/hospital is one of the twelve sites that we have 
randomly chosen to be part of this study. 
 
You are invited to participate in this study. 
 
What is expected from the participants of this study? 
I would like to conduct an interview the manger of the PMTCT programme at your 
facility.  My interview will consist of 31 questions about the running of the programme. 
I would also like to interview mothers who have delivered babies in the last 48 hours and 
review their files and antenatal cards and would like to review clinic/hospital registers. 
 
The duration of the entire evaluation will be no longer than two to three days. 
 
May I withdraw from the study? 
Your participation is completely voluntary.  You may withdraw from this study at any 
time.  If you choose to withdraw or not to participate in the study it will have no negative 
effects on your work relationship in any way. 
 
What about confidentiality? 
Patient and provider information will remain confidential. Allocating study numbers will 
protect anonymity of participants. 
 
I have acquired permission from the Local and Provincial health authorities to conduct this 
study. 
 
A summary of the findings from all the sites combined will be available to your 
MOU/hospital once the research is completed. I will not receive any direct benefits from 
doing this study. 
 
If you have any queries you can contact me at (011) 481-5196 or the chairperson of the 
Human Research Ethics Committee at University of Witwatersrand, Prof Cleaton-Jones at 
(011) 717-2229. 
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If you are happy to participate please read and sign the attached consent form. 
 
Thank you for your time.  
 
 
 
Dr F Ismail 
Department Of Paediatrics and Child Health 
University of Witwatersrand 
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APPENDIX H 
 
A DESCRIPTIVE STUDY OF ASPECTS OF THE PREVENTION OF MOTHER 
TO CHILD TRANSMISSION OF HIV PROGRAMME AT SELECTED 
HOSPITALS AND CLINICS IN GAUTENG 
 
 
CONSENT FROM PARTICIPANT 
 
I, _________________________________hereby consent to participate in the Prevention 
of Mother to Child Transmission of HIV Programme evaluation study. 
The study has been explained to me and I understand what the study will entail. 
I consent to an interview and a review of my records.  
I understand that all information will be kept confidential 
I understand that I can withdraw from the study at any time and this will not affect my or 
my baby’s care in the ward. 
 
Signed______________________ 
 
Date: _______________________ 
 
Place: ________________________ 
 
Witness: ______________________ 
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